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Abstract 
 
 
 In this thesis, molecular dynamics simulations, molecular docking, and homology 
modeling methods have been used in combination to design possible inhibitors as well as to 
study the structural changes and function of target proteins related to diseases that today are in 
the spotlight of drug discovery. The inwardly rectifying potassium (Kir) channels constitute the 
first target in this study; they are involved in cardiac problems. On the other hand, tensin, a 
promising target in cancer research, is the second target studied here.   
 The first chapter includes a brief update on computational methods and the current 
proposal of the combination of MD simulations and docking techniques, a procedure that is 
applied for the engineering of a new blocker for Kir2.1 ion channels and for the design of 
possible inhibitors for Tensin.   
 Chapter two focuses in Kir ion channels that belong to the family of potassium-selective 
ion channels which have a wide range of physiological activity.  The resolved crystal structure of 
a eukaryotic Kir channel was used as a secondary structure template to build the Kir-channels 
whose crystallographic structures are unavailable. Tertiapin (TPN), a 21 a.a. peptide toxin found 
in honey bee venom that blocks a type of Kir channels with high affinity was also used to design 
new Kir channel blockers. The computational methods homology modeling and protein-protein 
docking were employed to yield Kir channel-TPN complexes that showed good binding affinity 
scores for TPN-sensitive Kir channels, and less favorable for Kir channels insensitive to TPN 
 viii 
block. The binding pocket of the insensitive Kir-channels was studied to engineer novel TPN-
based peptides that show favorable binding scores via thermodynamic mutant-cycle analysis.   
 Chapter three is focused  on the building of homology models for Tensin 1, 2 and 3 
domains C2 and PTP using the PTEN X-ray crystallographic structure as a secondary structure 
template. Molecular docking was employed  for the screening of druggable small molecules and 
molecular dynamics simulations  were also used to study the tensin structure and function in 
order to give some new insights of structural data for experimental binding and enzymatic 
assays. 
 Chapter four describes the conformational changes of FixL, a protein of bradyrhizobia 
japonicum. FixL is a dimer known as oxygen sensor that is involved in the nitrogen fixation 
process of root plants regulating the expression of genes.  Ligand behavior has been investigated 
after the dissociation event, also the structural changes that are involved in the relaxation to the 
deoxy state. Molecular dynamics simulations of the CO-bound and CO-unbound bjFixL heme 
domain were performed during 10 ns in crystal and solution environments then analyzed using 
Principal Component Analysis (PCA). Our results show that the diffusion of the ligand is 
influenced by internal motions of the bound structure of the protein before CO dissociation, 
implying an important role for Arg220. In turn, the location of the ligand after dissociation 
affects the conformational changes within the protein. The study suggests the presence of a 
cavity close to the methine bridge C of the heme group in agreement with spectroscopic probes 
and that Arg220 acts as a gate of the heme cavity. 
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Chapter 1 
Computational Methods 
 
Molecular Dynamics Simulations 
 The first molecule studied by MD simulations was bovine pancreatic trypsin inhibitor 
(BPTI), a protein considered small since it has 58 residues.  The simulation was done for 8.8 ps 
in vacuum1.  The continuously growing computer power nowadays, permits simulations of 
bigger systems (104-106 atoms) and simulation times of ns or µs2.  Due to this, MD Simulations 
have been recognized as a widely used tool to study biomolecular systems. Currently, results of 
extended simulation runs can be compared to experimental studies; moreover, the structures that 
have been determined by X ray or NMR methods can be improved by MD, which makes it a 
complimentary tool.  
There are three areas of application of MD simulations; the first one is to give 
information about the dynamics on different timescales of biomolecules in their natural 
environment, in solution;  internal motions, conformational changes or even protein folding 
processes, followed by the analysis of the thermal averages of molecular properties including 
interaction energies and entropies and finally the exploration of  conformational space3,4.  
The  solvent surrounding the protein has been developed into a more realistic description 
that includes explicit solvent molecules around protein, the counterions addition in order to 
neutralize the system, a naturalistic treatment of the system boundaries, and a more correct 
treatment of long-range electrostatic forces.  The effect of the solvent on a protein can also be 
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studied in a simulation to collect information of the biomolecular system such as time-averaged 
properties like density, conductivity, and dipole moment4.  
Improvement in methologies has been also made. Force field parameters have been 
updated and now include many atoms in the periodic table; long range electrostatic interactions 
are now considered explicitly and pairwise electrostatic interactions are improved for the effect 
of the polarizable surroundings outside a cutoff radious5. In the case of system boundary 
conditions, the most used method is periodic boundary conditions since it avoids abrupt borders 
with vacuum and works  to include artificial periodicity into the system4. Also better algorithms 
used to control temperature and pressure have been proposed and currently used by MD 
programs6-8.  
Prevalent programs to perform MD simulations of biomolecules include Amber9, 
CHARMM10, GROMOS11, NAMD12 and Desmond13 among others.  
 
Molecular Docking 
 Docking involves the process of binding a small molecule to a target protein. Several 
factors affect this process  making it quite complex; for example, the motion of the ligand and 
receptor which affects the possible interactions solvent-receptor-ligand-solvent present according 
to the molecular distribution of charges4. 
 Most common docking programs include, DOCK14, AutoDock15, FlexX16, GOLD17, 
GLIDE18, and DOT19 among others. 
In the case of GLIDE, the molecular probe that could be a potential drug is searched 
using a hierarchical series of filters which give possible sites where the ligand can bind to the 
receptor active-site, this finally results in a ligand pose18. The accuracy of the score of a ligand 
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pose is based in diverse sets of fields within a grid that represents the shape and properties of the 
receptor. The conformation of the ligand is changed in order to search for more suitable 
conformations and this together with a heuristic screening eliminates unwanted conformations18. 
GLIDE works well for small molecules with a limit of 300 atoms per ligand. 
When the ligand is bigger than 300 atoms and the problem requires the docking of a 
peptide DOT2.0 can be used. DOT is a shape based molecular docking program that performs a 
rigid body search of the ligand molecule (or the mobile molecule), translated and rotated about 
the stationary molecule which is the receptor19.  
 
Combining Docking and MD Simulations 
 In order to have a reliable model of the complex ligand-receptor docking techniques have 
recently been combined with MD simulations. Docking is used to search for conformations of 
the ligands, and ultimately involves the screening of huge libraries of drug-like compounds in a 
short time period. The problem here is that the conformation of the receptor is not allowed to 
change in the binding process.  In this sense, MD is a tool that can add some flexibility to the 
receptor and ligand permitting some adjustment upon the binding event. Figure 1 shows a 
scheme for the combination of the techniques in some steps of the drug discovery process4.  
Different approaches have been developed for the MD inclusion before or after the docking 
process.   During the receptor structure preparation multiple conformations of the receptor can be 
generated and  subsequently subjected to docking  as an ensemble20. 
 Another approach includes  so called “soft docking” that consist of allowing the ligand 
to “penetrate” the surface of the protein in order to account for localized changes that could 
occur in a more flexible environment21. The addition of some flexibility to the side chains in the 
 4 
active site after ligand binding, constitute a different approach, here a series of rotamer libraries 
are used to search for different conformations of the involved side chains22.    
 
 
Figure 1 Scheme of the Protocol of a Drug Design Process, when the Structure of the Target is 
known or can be modeled4. Brackets include steps that are not always done. Gray shades include 
steps in which MD simulations can be performed4. 
 
 
 MD simulations are known to help to refine the resultant docking complexes. The 
dynamics can add some flexibility to the receptor and ligand, improving their assembly and 
enhancing the intermolecular interactions between them. Moreover, the stability of the complex 
structure during a simulation trajectory indicates that the complex is realistic and it was correctly 
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docked. Another important feature of running MD after docking is the interaction of the solvent 
with the complex and the solvent molecules effect on the stability of the ligand’s docked pose. 
 Since most of docking algorithms do not take into account the mobility of the receptor or 
the interactions with the molecules in the explicit solvent, MD simulations can be used to 
enhance a docking protocol4.  
 
Homology Modeling 
 When a target protein or enzyme structure is not available experimentally from an X-ray 
or NMR experiments, the structure can be predicted using its amino acid sequence and a 
structural template from an available experimentally defined structure with high accuracy. The 
template must be at least 40% similar to the sequence of interest. 
 According to reported investigations23, the homology modeling process involves seven 
steps, the template recognition and initial alignment followed by the processes of alignment 
correction and backbone generation, then the loop and side chain modeling finalizing with the 
model optimization and validation23. 
In the first step an initial sequence alignment has to be performed, the percentage of 
identity between the query sequence and the secondary structure template candidate should be 
high enough as shown in Figure 2.  A BLAST24 or FASTA25 search can be done in order to find 
possible candidates. These programs make a comparison between the sequence of interest and all 
sequences of known structures in the PDB bank using a residue exchange matrix and an 
alignment matrix23. The results are shown according to the percentage of identity as a list of hits. 
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Figure 2 The Two Zones of Sequence Alignments23 
 
The second step involves the alignment correction where some regions of the sequence 
of interest or gaps have to be corrected by examining the secondary structure of the template or 
by using multiple sequence alignments. 
The third, fourth and fifth steps involve the building of the model considering the 
secondary structure of the template, which mean the presence of alpha helices or beta strands, as 
well as the modeling of loops. 
The optimization of the model that includes the use of MD simulations to perform 
minimization of energy or simulated annealing, is performed in order to have more energetically 
favorable structures, avoiding atom overlaps. 
And finally the model validation which is usually done by methods that evaluate 
homology models by checking the stereochemical quality of the new structure, verifying the 
accuracy of parameters like bond angles, bond lengths, correctness of amino acid chirality and 
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comparing the different φ and ψ backbone dihedral angles within the new structures to the ones 
in the X ray structure. 
Homology modeling provides a helpful tool for drug design since unavailable target 
structures can be predicted, in order to be subsequently screened against drug-like compounds 
and learn about their structures and possible function.   
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Chapter 2 
Docking of the European Honey Bee Venom Peptide Tertiapin in the Inwardly Rectifying 
Potassium (Kir) Channels using Homology Models 
Introduction 
Inwardly rectifying potassium (Kir) channels are a specific subset of potassium selective 
ion channels that show greater flow of ions into rather than out the cell.  These channels were 
first described as anomalous K+ rectifiers due to the differences they showed with respect 
voltage-gated K+ (Kv) channels.1 They play an important role in the maintenance of the resting 
membrane potential and in regulation of the duration of the action potential in electrically 
excitable cells (i.e. cardiac muscle).2 
The structures of Kir channels in general contain a motif of two putative membrane-
spanning domains (TM1 and TM2) (Figure 3). These membranes are attached by an extracellular 
pore-forming region (H5), a cytoplasmic amino (NH2)- and carboxy (COOH)- terminal 
domains.2  This is known as the elemental portion present in all types of inwardly rectifying 
potassium channel. The main function of the H5 region is as “ion-selectivity filter” which 
signature sequence T-X-G-Y(F)-G is similar to other K+-selective ion channels.3,4 
Kir channels are present in a wide number of cell types: cardiac myocytes5, neurons6, 
blood cells7, osteoclasts8, endothelial cells9, glial cells10, epithelial cells11, oocytes12 and 
kidneys13. G protein-gated K+ (KG) channels and ATP-sensitive K+ (KATP) channels also show 
inward rectification and so belong to the Kir channel family14, 15. Seven Kir subfamilies have 
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been identified (Kir1.x to Kir7.x) (Figure 4). These subfamilies are subdivided into four 
functional groups: Classical Kir channels (Kir2.x), G protein-gated Kir channels (Kir3.x), ATP-
sensitive K+ channels (Kir6.x), and K+-transport channels (Kir1.x, Kir4.x, Kir5.x, and Kir7.x)14.  
The fact that the basic Kir channel subunits are highly similar, allows the formation of functional 
Kir channels in homotetrameric and heterotetrameric combinations. Usually heteromerization 
takes place between members of the same subfamily, an example of that could be the 
heterotetrameric complex of Kir3.1 with Kir3.4.1, 2 
 
 
 
 
 
 
 
 
Figure 3 Membrane Spanning Domains (TM1-TM2).2 
 
The physiological function of the Kir channels relies on regulation of pore opening, ion 
flux, and channel localization in the cell.  Ions, polyamines, nucleotides, lipids, and some 
intracellular proteins are factors that regulate pore opening and ion flux, interacting with 
fundamental elements of the Kir channel. The localization of the channels in specific regions of a 
cell, contributes to the different roles of the Kir channels in different tissues, an example of this 
could be the apical or basolateral membranes of epithelial cells or pre- or postsynaptic sites in 
neurons, they are also involved in a wide number of cardiac and neurological diseases.2 
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Figure 4 Kir-Channels Subfamilies.2 
 
Cs+ and Ba2+ have been identified as generic inhibitors of most Kir channels; usually they 
have been used to study their physiological function in native cells and tissues.16 Tertiapin, a 
toxin constituent of the honey bee venom, has been reported as a potent inhibitor of Kir1.1 and 
Kir3.1/3.4 channels with nanomolar binding affinity. The cardiac Kir3.1/3.4 controls the 
pacemaker activity, while the renal Kir1 regulates salt reabsorption.  Kir1 has been involved in 
genetic defects specifically in the type II Bartter’s syndrome that causes characteristic volume 
depletion and hypotension.  However, classical Kir2.x channels are insensitive to all the known 
Kir channels blockers and are known to be involved in cardiac diseases like the Andersen–Tawil 
syndrome.17, 18 
The present study is focused on the homology modeling of the extracellular vestibule of 
three different Kir channels Kir1.1, Kir2.1 and the heteromer Kir3.1/3.4, using as template the 
crystal structure of the chicken Kir2.2 channel (cKir2.2). The models of Kir 1.1 and Kir3.1/3.4 
channels have been protein-peptide docked with the solved solution structure of the bee venom 
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peptide tertiapin, the results of the protein-peptide docking simulations were compared to 
reported in vitro functional binding data for human Kir3.4 and Kir1.1 channels, and human 
Kir2.1 which has very low binding affinity to wild type tertiapin.  Kir2.1 is of special interest 
since these Kir channels have been involved in cardiac diseases and currently there are not 
known inhibitors, so based on the facts that Tertiapin lacks negatively charged residues and 
Kir2.1 possess positively charged residues within its vestibule, iterative mutagenesis of tertiapin 
was performed to engineer a peptide that docks selectively to Kir2.1, in order to perform the 
subsequent synthesis and testing on Kir2.1 channels expressed in vitro using standard 
electrophysiological methods. 
 
Homology Modeling Kir Channels 
The structures of the extracellular portions of the channels Kir1.1, Kir2.1 and the 
heteromeric channel Kir3.1/3.4 were not available so they were built using the 3.1Å crystal 
structure of the homomeric form of the Kir2.2 channel as a template (PDB code 3JYC)19 and the 
amino acid sequences of Kir1.1, Kir2.1 and Kir3.1/Kir3.4.20 Since the Kir2.2 pdb file included 
just only one subunit, the 3 other subunits were built using the symmetry matrix reported in the 
pdb file and DeepView/Swiss-pdbViewer21, then the models were prepared using the preparation 
wizard of Maestro, version 9.3, Schrödinger22, and later subjected to energy minimization with 
MacroModel to reduce any bad contacts . The structure prediction was done by Prime Structure 
Predictor of the Schrodinger suite version 3.120.   
Kir1.1, Kir2.1 and the heterotetrameric Kir3.1/3.4 turrets were modeled as chimeras on 
the intracellular portion of Kir2.2 as Figure 5 shows, with average sequence identities close to 
90%.  
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Figure 5 Ion Channel Structures with Extracellular Portions in VDW Representation. 5a, 
secondary structure template Kir 2.2 ion channel. 5b, Kir 1.1ion channel model. 5c, Kir2.1 ion 
channel model. 5d, Kir 3.1/3.4 heteromultimeric ion channel model. 
 
These models were then evaluated, aided by Ramachandran plots with the program 
Procheck23, which checks the stereochemical quality of a given protein structure by verifying the 
accuracy of parameters like bond angles, bond lengths, correctness of amino acid chirality and 
compares the different φ and ψ backbone dihedral angles within the new structures to the ones in 
known X-ray structures. 
Figure 6 shows that most of the aminoacids in Kir 1.1 ion channel model are located 
within favored regions in the Ramachandran plot.  The majority of residues are in the alpha helix 
(A), beta strand (B) and left alpha helix (L) allowed regions of the plot which indicates that the 
model was built correctly. The figures show an improvement after minimization of the modeled 
ionchannel, the number of residues in disallowed regions decreases from 13 to 8. 
 The residue Glycine (shown as triangles) is least restricted since contains just one 
hydrogen for its “sidechain”; this is demonstrated in the plot where the area where its dihedrals 
a b 
c 
d 
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angles are considered correct is larger.  On the other hand, the residue Proline, with its 5-
membered-ring side chain shows only a small number of possible combinations of ψ and φ. 
Other residues that remain in disallowed regions are not part of the binding site. 
 
 
 
 
 
 
 
 
Figure 6 Ramachandran Plot of Kir1.1 Ion Channel Model. 6a, before minimization and 6b, after 
minimization. 
 
Table 1 Plot Statistics according to Model Minimization (Figure 6) 
 
 
 Ramachandran plots in figure 7 shows a markedly decrease in residues in disallowed 
areas from 16 to 5 (Table 2) after minimization of Kir2.1 model.  However, the majority of 
residues are in allowed regions, which implies that secondary structure of the model is correct. 
Residues in most favored regions (A, B, L) 1027 87.6% 1032 88.1% 
Residues in additional allowed regions (a,b,l,p) 118 10% 116 9.9% 
Residues in generously allowed regions (~a,~b,~l,~p) 14 1.2% 16 1.4% 
Residues in disallowed regions 13 1.2% 8 0.7% 
Number of end-residues (exc. Gly and Pro) 40 -- 40 -- 
Number of glycine residues  64 -- 64 -- 
Number of proline residues 56 -- 56 -- 
Total number of residues 1332 -- 1332 -- 
a b 
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In a like manner, in Figure 8, most of the residues are in the alpha helix (A), beta strand 
(B) and left alpha helix (L) allowed regions of the plot which implies models were built correctly 
and the residues that fall in the disallowed regions are not part of the extracellular portions of the 
ion channel models.  
 
 
 
 
 
 
 
 
Figure 7 Ramachandran Plot of Kir2.1 Model. 7a, before minimization and 7b, after 
minimization. 
 
 
Table 2 Plot Statistics according to Model Minimization (Figure 7) 
	  
 
 
 
 
 
 
 
Residues in most favored regions (A, B, L) 
Before After 
1004 83.1% 1026 85% 
Residues in additional allowed regions (a,b,l,p) 164 13.5% 159 13.2% 
Residues in generously allowed regions (~a,~b,~l,~p) 24 2% 18 1.4% 
Residues in disallowed regions 16 1.4% 5 0.4% 
Number of end-residues (exc. Gly and Pro) 8 -- 8 -- 
Number of glycine residues  64 -- 64 -- 
Number of proline residues 44 -- 44 -- 
Total number of residues 1324 -- 1324 -- 
a b 
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Figure 8 Ramachandran Plot of Kir3.1/3.4  Model. 8a, before minimization and  8b, after 
minimization. 
 
Table 3 Plot Statistics according to Model Minimization (Figure 8) 
 
 
 
 
 
 
 
Docking Wild Type Tertiapin 
Tertiapin is a peptide contains 21 amino acids (Figure 9), it has six positively charged 
residues, four of which are clustered within the C-terminal half of the polypeptide chain. 
Negatively charged residues are totally absent in Tertiapin, and the lysine at the carboxyl end is 
in an amide form. It presents four cysteines that form two disulfide bonds. According to solution 
Residues in most favored regions (A, B, L) 
Before After 
1010 85.5% 1016 86% 
Residues in additional allowed regions (a,b,l,p) 158 13.4% 156 13.2% 
Residues in generously allowed regions (~a,~b,~l,~p) 8 0.7% 6 0.5% 
Residues in disallowed regions 5 0.4% 3 0.3% 
Number of end-residues (exc. Gly and Pro) 28 -- 28 -- 
Number of glycine residues  60 -- 60 -- 
Number of proline residues 40 -- 40 -- 
Total number of residues 1309 -- 1309 -- 
a b 
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NMR experiments this peptide contains a type-I reverse turn and one α-helix, which are 
connected by a loop of an extended β-sheet.24,25 
The homology models, free of water were used as a stationary molecules to simulate 
docking by Tertiapin (PDB code 1TER)24. The simulation allowed the translational motion of the 
peptide which structure was solved by NMR.  The PDB file contains 21 snapshots of the peptide 
in solution. 
The first snapshop of wild tertiapin structure in solution was taken as starting coordinates 
to run an MD simulation of 10 ns duration. The simulation was performed with Desmond 3.126 
using the OPLS force field27 in order to study the flexibility of the peptide and to obtain a 
equilibrated structure of tertiapin for subsequent docking studies. 
 
 
Figure 9 a, Tertiapin Structure in New Cartoon Representation showing Disulfide Bonds 
between Cysteines. 9b, Tertiapin Structure in VDW Representation showing Positively Charged 
Residues in Blue. 
 
In Figure 10, the root mean square fluctuations (RMSF), that measures the deviation 
between the position of an atom and a reference position averaged over time, shows that the first 
three residues close to the N-terminus are more mobile, which is expected since they are at one 
terminus of peptide.  However, the rest of the peptide residues do not show significant 
a b 
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fluctuations due to the presence of the disulfide bonds, hence low flexibility was shown by the 
peptide structure.   
Root mean square deviations (RMSD) measures the average distance between the 
backbone atoms of superimposed proteins or peptides, these calculations showed equilibration of 
Tertiapin structure after MD simulations (Fig 11), the automated docking of the resultant 
Tertiapin structure was then performed using the DOT 2.0 software28. The program calculates 
partial atomic charges at heavy atoms and polar hydrogens for the moving molecule and uses  
programs like REDUCE29 to add hydrogens to all the molecules present in the calculation. 
 
 
Figure 10 Residue Mean Square Fluctuations (RMSF) of Tertiapin Structure during 10 ns of 
Molecular Dynamics Simulation.  
 
MSMS30 another employed program in DOT calculation, it describes the shape of the 
stationary molecule by an excluded volume surrounded by a 3 Å layer, rolling a probe sphere of 
radius 1.4 Å. The calculation of the electrostatic potential of the stationary molecule is performed 
by APBS31, the calculation is done at heavy atoms and polar hydrogens, restricted to the solvent 
surface. Grid size was set to 384 Å, to make sure that under periodic conditions the relatively 
R
M
SF
 (Å
) 
Residues 
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small toxin Tertiapin was not influenced by the shape or electrostatic properties of the large 
stationary molecule in adjacent cells. Required grid space was 1 Å.  The contacts between the 
receptors and the ligand were then calculated using Pymol32. 
 
 
 
Figure 11 Residue Mean Square Deviations (RMSD) of Tertiapin Structure during 10 ns of 
Molecular Dynamics Simulation.  
 
Docking with the software DOT was peroformed using 6 degrees of orientational 
searching in order to obtain the widest number of samples. All of these resulted in an average of 
54,000 placements, which were preferred based on electrostatic and van der Waals terms. DOT 
computes two scores directly, electrostatic energy (from the Poisson-Boltzmann electrostatic 
model) and pseudo-van der Waals energy. The binding score is sorted on the sum of the two 
scores.28 Table 4 presents the resultant binding scores of the docking of Tertiapin in the Kir 
channel models 1.1, 2.1 and 3.1/3.4 according to the 6 degrees of rotation of the mobile 
molecule, the 10 top ranking placements, evaluated also on the basis of pair wise atomic contact 
energy, are shown. 
Time (ns) 
R
M
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 (Å
) 
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According to the literature in vitro experiments have shown that Tertiapin (TPN) is a 
potent blocker of Kir1.1 and Kir3.1/3.4 channels.  It is been reported that TPN inhibits 
homotetrameric Kir1.1 with a Kd of ~1 nM and heterotetrameric Kir3.1/3.4 with ~10-fold lower 
affinity. Affinity of the channel for TPN relies in the side chains present in the turrets of the 
Kir3.4 portion, while the Kir3.1 turrets have shown to be insensitive towards tertiapin in the 
homomeric form25. Table 4 shows that Kir1.1 presents the best binding scores with wild 
Tertiapin followed by Kir3.1/3.4 scores. In the case of Kir2.1, the binding scores were the worst 
ones as expected, some of the ligand structures were docked within the intracellular portion of 
the Ion channel.  
 
 
Table 4 Binding Scores of Docking Tertiapin in the Kir Channel Models (Kcal/mol).  
 
 
 
 
 
 
 
The difference between snapshots in Tertiapin structure was also studied; in Figure 12, 
the root mean square deviation (RMSD) between the 21 structures was calculated.  Two different 
groups are defined according to the difference in their conformations.  Snapshots 1 and 4 belong 
to the first group of conformations; snapshot 16 belongs to the second group, according to 
Kir1.1 Kir2.1 Kir3.1/3.4 
-26.5189  -15.0003  -20.7737  
-26.0221  -14.7172  -20.7728  
-25.4607  -14.6265  -20.7532  
-25.2764  -14.5433  -20.6582  
-24.9414  -14.4305  -20.6385  
-24.8365  -14.4269  -20.4495  
-24.8284  -13.9493  -20.2543  
-24.7091  -13.8682  -20.2396  
-24.4714  -13.7651  -20.2325  
-24.4351  -13.7626  -20.2099  
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RMSD calculations.  RMSD measures the deviation between the position of an atom and a 
reference position taking the average over the particles, giving time specific values. 
 
Figure 12 RMSD Calculations between Snapshots of the NMR Structures of TPN PDB file, 
Code 1TER. 
 
These structures were also docked in the Kir1.1 model to study the difference in ligand-
receptor interactions with respect to the change in conformation in the ligand, the binding scores 
are in the following table. 
 
Table 5 Binding Scores of Docking Tertiapin Different Conformations in the Kir Channel 
Models (Kcal/mol). 
Kir1.1 Kir2.1 
TPN1 TPN4 TPN16 TPN1 TPN4 TPN16 
-26.4083 -28.3945 -26.4268 - -21.9437 - 
-26.164 -28.2702 -25.4882 - -16.1295 -16.6184 
-25.9028 -27.9354 -25.2821 - - - 
-25.656 -27.7951 -25.1244 - - - 
-25.613 -27.6543 -24.7812 - - - 
-24.8497 -27.1872 -24.7202 - - -15.9899 
-24.6872 -26.7921 -24.7156 - -15.4565 -15.8499 
-24.2163 -26.4051 -24.4598 - - - 
-24.1963 -25.9512 -24.4103 -14.2853 - - 
-24.1206 -25.8222 -24.2396 - -16.3782 - 
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Binding scores were similar to the ones already shown; Kir1.1 shows very good binding 
scores for all the three cases, with no difference resulting from the change of conformation of 
Tertiapin while in the case of Kir2.1 bad docking scores were obtained and in most of the cases 
no docking poses were observed in the extracellular portion of the ion channel.  
 
Molecular Dynamics of the Complex 
 
In order to prove stability of the complexes, each one of the ion channel-peptide 
coordinates of the complexes that corresponded to the top binding scores were prepared using the 
VMD program (Visual Molecular Dynamics version 1.9.1)33 for molecular dynamics simulation.  
Simulations were performed with Desmond 3.126 using the OPLS force fields27. Periodic 
boundary conditions were used and the initial structure was placed in an equilibrated water box. 
To create a neutral simulation box Cl- ions were placed instead of water molecules at the most 
positive electrical potential. The system was minimized during 100 ps, then was heated to 300K 
during 600 ps and equilibrated at constant volume for 400ps. A standard MD trajectory 10ns 
long, at constant pressure and temperature, was performed. The integration time step was 2fs. 
Figure 13 shows that the root mean square deviation (RMSD) calculations of the 
simulations of the top poses complexes of the Ion channels and Tertiapin structures become 
stable after 5 ns of simulation. Simulations were performed to release any overlapping atoms in 
the complexes after rigid body docking. 
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Figure 13 RMSD Calculation of the Kir Channels-Tertiapin Complex during Molecular 
Dynamics Simulations. 
 
Table 6 shows the interactions between the ligand and binding site in the ion channel 
models calculated in pymol with list contacts within 3 Å script. 
Hydrophobic, Van der Walls and ionic interactions are present between these residues in 
receptor and ligand. Kir1.1 shows more interactions with Tertiapin than Kir3.1/3.4. The ionic 
interaction between the negative residue Glu83 and positive residues Lys16, Lys17 in tertiapin 
are present; also interactions with the phenylalanine ring Phe106, Phe105 and Phe108 in the 
center of binding site are seen in table 5. Kir1.1 also interacts with tertiapin through residues 
Glu82 and Met13. In the heteromultimeric chimera Kir3.1/3.4, the ligand presents important 
interactions just with chains C and D that belong to Kir3.4 extracellular turret in agreement with 
experimental studies 
 25 
Table 6 Interactions between Kir1.1 and Kir3.1/3.4 Ionchannels and Wild Tertiapin 
Ion Channel Receptor Ligand Receptor Ligand 
Kir1.1 
(A)Phe72  Ala1  (C)Glu83  Lys16  
(A)Tyr73  Ala1, Pro11  (C)Asn84  His12, Lys16  
(A)Glu83  Met13  (C)Gly105  Met13, Lys16  
(A)Asn84  Ala1, Leu2  (C)Phe106  Met13, Lys16  
(A)Tyr104  Lys17  (C)Phe106 His12  
(A)Gly105  Met13, Lys17  (C)Arg107  Met13  
(A)Phe106  Leu2, Met13 (C)Phe108  Lys16  
(A)Phe106  Cys3, Cys14  (D)Tyr73  Cys5, Asn6  
(A)Phe106 Ala1, Pro11  (D)Tyr73  Asn4, Arg7  
(A)Arg107  Leu2  (D)Pro74  Cys3,Asn4  
(A)Phe108  Met13  (D)Pro74  Asn6, Arg7  
(A)Phe108  Met13  (D)Pro74  Leu2  
(B)Tyr73  Gly19  (D)Asp76  Asn4  
(B)Pro74  Gly19  (D)Glu83  Cys3  
(B)Glu83  Gly19, Lys20  (D)Asn84  Lys17  
(B)Gly105  Lys17  (D)Tyr104  Lys17  
(B)Phe106  Lys16, Lys17  (D)Gly105 Lys17  
(B)Phe108  Lys17  (D)Phe106 Cys18, Gly19  
(C)Tyr73  His12, Trp15  (D)Phe108  Leu2  
Kir3.1/3.4 
(A)Lys71  Ile9, Pro11  (C)Ile78  Lys17  
(A)Tyr103  Ala1  (C)Pro79  Lys17  
(A)Gly104  Leu2  (C)Glu83  Lys17  
(A)Tyr105  Ala1, Leu2  (C)Asn83  Met13  
(B)Lys71  Cys5, Cys18  (C)Gly104  Leu2  
(B)Lys71  Lys17, Gly19  (C)Phe105  Met13  
(B)Ala72  Cys5, Lys20 (C)Thr109  Lys17  
(B)Ala72  Cys18  (D)Val  Arg7  
(B)His73 Cys5, Asn6  (D)Glu82 Ala1  
(B)Val74  Asn6  (D)Asn83  Ala1, Asn4  
(B)Gly104  Leu2, Asn6  (D)Gly104  Leu2  
(B)Tyr105  Cys3, Lys17  (D)Phe105  Ala1, Leu2  
(C)Val72  Lys16  (D)Phe105  Cys3, Asn4  
(C)Gly73  Lys16  (D)Phe105  Asn6, Arg7  
(C)Asp74  Lys16  (D)Val107  Ala1, Leu2  
 
On the other hand, Figures 14-16 show the contact maps between Kir1.1 and different 
conformations of Tertiapin to compare and study the influence of the conformational variation of 
Tertiapin structure in the interactions with the binding site. 
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Figure 14 Contact Map of Kir1.1 Bound to Tertiapin Conformation 1. 
 
The interactions of Kir1.1 with TPN1 are mainly in the center of the peptide from 
residues Ile10 to Lys16. In this portion of the peptide, important ionic interactions are present 
between Glu83 and His12, Lys16 and Lys21.  Moreover, hydrophobic interactions are shown 
between Phe106 and Pro11, Met13 and Trp15. 
The TPN4 conformation shows more interactions including the four chains of Kir1.1, 
even though TPN4 binding is oriented the same way that TPN1.  The central portion of the 
peptide shows ionic and hydrophobic interactions including the same residues in the case of 
TPN1 but also interactions of with residues close to the C-terminus of the peptide are shown 
along all residues of the binding site.      
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Figure 15 Contact Map of Kir1.1 Bound to Tertiapin Conformation 4. 
 
In Figure 16, interactions between the TPN16 conformation and Kir1.1 are shown, 
although in this case the binding scores were as good in TPN1 and TPN4; the interactions show 
that the orientation of the peptide is not the same and that the ligand is binding further out the 
binding site due to its conformation, this is shown in Figure 17. 
Since the Kir1.1 and Kir2.1 turrets share some residues that show interactions with the 
central portion of Tertiapin and its positively charged residues, these residues have been included 
in the novel peptide that selectively binds to Kir2.1 turrets that has been engineered in order to 
propose a possible blocker for this ion channel.   
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Figure 16 Contact Map of Kir1.1 Bound to Tertiapin Conformation 16. 
 
Engineering a Peptide Selective for Kir2.1 Ionchannel 
Due to the lack of potential blockers for the Kir2.1 channel, and since the affinity of 
Kir2.1 for TPN is low, an engineered peptide has been designed to selectively block Kir2.1 and 
hopefully obtain better binding affinities.  
In order to study the differences and similarities between binding sites, they were 
evaluated by Sitemap 2.2, a tool contained in the Maestro Schrodinger suite that identifies 
potential binding sites and predicts their druggability.  The chosen grid was of 15 site points with 
a cut off of 4 Å from the nearest site point. 
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Figure 17 Tertiapin Conformation 16 in Kir1.1 Ionchannel:  Peptide is not embedded in binding 
pocket. 
 
In Sitemap, the calculation is done in three stages, the first involves the search of one or 
more regions on the protein surface suitable for binding of the ligand to the receptor; to locate 
sites, a grid of points called “site points” is used depending on how close they are to the protein 
surface and solvent accessibility34.  Sitemap uses the OPLS-2005 force field.35  
The second generates contour maps (site maps) divided into hydrophobic and hydrophilic 
maps. The hydrophilic maps are further divided into donor, acceptor, and metal-binding regions. 
The evaluation stage concludes with the calculation of properties like site score, size, exposure 
score, enclosure, contact, hydrophobic/hydrophilic character and donor/acceptor character. These 
scores were previously derived running the SiteMap program on several proteins bound to their 
inhibitors with potencies in the submicromolar range and executing statistical analyses that 
resulted in optimized scores.34  
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According to Halgren34 132 is the average number of site points for submicromolar sites, 
the druggability score (Dscore) answer the question of whether the site is druggable or not, the 
results in the studies by Halgren suggest that a good average for the submicromolar site for site 
score is 1.01. The size of a binding site is related to the number of site points contained within a 
putative site, exposure scores are considered lower the better, being 0.52 the average for 
submicromolar sites while higher enclosure scores are good with an average of 0.76 for 
submicromolar sites.  In the case of contact score, the average is 1, which is also the average for 
the hydrophobic/hydrophilic character and finally for the donor/acceptor character the average 
for the submicromolar sites is 0.76.  
 
Table 7 SiteMap Scores for the Binding Sites of Kir1.1 and Kir2.1 Models. 
Model SiteScore Size Exposure Enclosure HH character 
DA 
character 
V 
Kir 1.1 0.713 39 0.63 0.703 0.950 0.658 199.969Å3 
Kir2.1 0.938 178 0.66 0.640 1.235 1.846 486.717Å3 
 
 
In figure 18 and table 7, the difference between binding sites is observed; Kir1.1 turrets 
show a central hydrophobic site corresponding to the central phenylalanine ring reported in the 
literature.25 Also two hydrophobic sites in two of the turrets and small hydrophilic regions 
around the defined hydrophobic sites. 
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Figure 18 Sitemap Calculations showing Hydrophilic Regions in Red and Hydrophobic 
Regions in Blue. 18a, Kir1.1 Ion channel turrets model. 18b, Kir2.1 Ion channel turrets model. 
 
The scoring function used in Sitemap assesses the propensity of a site for ligand binding 
and ranks possible binding sites to eliminate those not likely to be pharmaceutically relevant; the 
binding site of this Ion channel has a site score of 0.713, on the other hand, Kir 2.1 turrets show a 
central hydrophobic region and small hydrophobic and hydrophilic regions spread throughout the 
turrets. The Main difference between turrets of Kir1.1 and Kir2.1 models results in wider 
hydrophilic sites in the turrets of Kir2.1 ion channel also in a better site score of 0.938. Most of 
the scores are close to the averages proposed for Halgren34 except for the donor/acceptor 
character of Kir2.1 binding site that is far from the average, this could be a consequence of its 
size and volume, which are bigger, compared to Kir1.1 binding site.  
The extracellular turrets of the ion channel models were also compared according to the 
charge of residues in order to have more insight about binding properties. Figure 19 shows the 
binding pocket of Kir2.1, Kir1.1 and Kir3.1/3.4.  Kir2.1 turrets differentiate from Kir1.1 and 
a b 
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Kir3.1/3.4 turrets in the number of positively charged residues present in the surface of binding 
pocket.  
Based on this fact, positively charged residues in the wild tertiapin (Lys and Arg) have 
been mutated to negatively charged residues (Asp and Glu), in order to add selectivity for the 
Kir2.1 ion channel to the engineered peptide, possible combinations and their corresponding 
binding scores in Kir2.1 are shown in Table 8. 
 
 
 
 
 
 
 
 
Figure 19 Ionchannel Turrets in VDW Representation Colored according Residue Charge. 
Neutral residues in yellow, positively charged residues in blue and negatively charged residues in 
red. 19a, Kir1.1 Ionchannel turrets; 19b, Kir3.1/3.4 Ionchannel turrets and 19c, Kir2.1 
Ionchannel turrets. 
  
Mutations to negatively charged residues close to the N-terminal of the peptide improve 
the binding score in cases of the models 1-4.  R7E and R7D mutations show the best scores in 
models 7 and 18 respectively, indicating that this position is key in binding to the Kir2.1 
Ionchannel. Model 11 shows a good binding score with the K20E additional mutation; however, 
the K20D mutation was not energetically favored.  Moreover, models 12 and 21 show favorable 
a b c 
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binding scores with the mutation K17E and K17D respectively. A trend regarding the chain size 
difference between the two negative residues Asp and Glu was not observed.    
 
Table 8 Binding Scores of the Modeled Peptides in Kir2.1 Ionchannel. 
Model  Score Sequence 
1 -19.8681  
2 -20.8892 
3 -20.6335 
4 -21.2707 
5 -17.0567 
6 -15.0982 
7 -25.0949 
8 ------- 
9 -18.9342 
10 ------- 
11 -22.3594 
12 -21.7680 
13 -17.0128 
14  -------  
15  -18.0145  
16  -14.9820  
17  -16.0145  
18  -23.3380  
19  -17.0146  
20  -14.0674  
21  -20.6593  
22  -------  
23  -17.4592  
24  -16.0324  
25  -16.7824  
26  -15.2858  
 
 Similar interactions are observed between Kir2.1 Ionchannel and peptide models 7 and 
11, shown in Table 10. Hydrophobic interactions are present between the phenylalanine ring of 
the Ion channel and residues Ile9, Ile10 and Pro11 of the modeled peptides, also van der Waals 
interactions with polar residues of the models are shown 
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Table 9 Interactions Present between Kir2.1 Ionchannel and the Modeled Peptides 7, 11.  
Model  Receptor Ligand Receptor Ligand 
Model 7 
(A)Asp75 Ala1 (B)Gly109 His12, Lys16 
(A)Thr78 Ala1 (B)Phe110 His12, Lys16 
(A)Ser79 Ala1,Asn4 (B)Phe110 Trp15, Lys21 
(A)Lys80 Asn4, Glu7 (C)Ser87 Trp15, Lys21 
(A)Lys80 Asn6 (C)Glu88 Ile9, Trp15 
(A)Ala84 Ala1 (C)Glu88 Lys21 
(A)Val86 Ala1 (C)Tyr108 Met13 
(A)Ser87 Ala1, Leu2 (C)Gly109 His12 
(A)Ser87 Pro11 (C)Phe110 His12, Trp15 
(A)Glu88 Ala1, Leu2 (C)Phe110 Ile9, Ile10 
(A)Glu88 Met13, Cys14 (C)Phe110 Pro11 
(A)Val89 Leu2 (C)Cys112 His12, Trp15 
(A)Asn90 Leu2 (D)Ser87 Lys17 
(A)Tyr108 Met13 (D)Glu88 Lys17 
(A)Gly109 His12, Met13 (D)Tyr108 Lys16 
(A)Phe110 Met13, Cys3 (D)Gly109 Met13, Lys16 
(A)Arg111 Met13 (D)Phe110 Lys16, Lys17 
(B)Tyr108 His12 (D)Cys112 Met13 
Model 11 
(A)Asp75 Ala1 (B)Tyr108 His12 
(A)Thr78 Ala1 (B)Gly109 His12, Lys16 
(A)Ser79 Ala1, Asn4 (B)Phe110 His12, Trp15 
(A)Lys80 Asn4, Glu7 (B)Phe110 Lys16, Lys21 
(A)Lys80 Asn6 (C)Ser87 Lys21, Trp15 
(A)Ala84 Ala1 (C)Glu88 Trp15, Lys21 
(A)Val86 Ala1 (C)Tyr108 Met13 
(A)Ser87 Leu2, Pro11 (C)Gly109 His12 
(A)Glu88 Leu2, Met13 (C)Phe110 His12, Trp15 
(A)Glu88 Cys14 (C)Phe110 Pro11, Ile9 
(A)Val89 Leu2 (C)Cys112 His12, Trp15 
(A)Asn90 Leu2 (D)Ser87 Lys17 
(A)Tyr108 Met13 (D)Glu88 Lys17 
(A)Gly109 Met13 (D)Tyr108 Lys16 
(A)Phe110 Met13, Cys3 (D)Gly109 Met13, Lys16 
(A)Phe110 Cys14 (D)Phe110 Lys16, Lys17 
  
 Common residues in the Kir Ionchannels interact with the central portion of the peptides, 
as well as in the case of the wild type tertiapin. In this case, ionic interactions are present through 
residue Glu88 and residues Lys17, and Lys21.Moreover, mutated residues in modeled peptides 
(Glu7) show ionic interactions with residue Lys80.  Mutated residue K20E in model 11 is not 
interacting with the Kir2.1 ion channel, however importance relays in the mutation R7E, which 
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is showing interactions with the receptor. Modeled peptides bind to Kir2.1 ion channel in the 
same orientation that wild tertiapin in Kir1.1 ion channel, binding scores improvement is due to 
the negative mutated residues in the peptides.   
 
Conclusion and Future Directions 
 Homology models of Kir1.1, Kir2.1 and Kir3.1/3.4 have been validated using ProCheck 
with >85% of residues in A, B and L allowed regions.  
 The interactions present between the Kir Channel models and the wild type Tertiapin are 
in agreement with the reported in experimental results and this also validates the homology 
models built. 
 Docking the engineered peptides in Kir2.1 show good binding results and this suggest 
these could be selective Kir2.1 ligands. 
 Calculations of Potential Mean Force (PMF) using steered Molecular Dynamics 
simulations will be used to study more deeply the interactions between the engineered peptides 
and the receptor and therefore obtain more selectivity towards the Kir2.1 channels.  
 The best scores involved in the docking of the mutated peptides in Kir2.1, will be 
synthesized and experimentally screened against Kir2.1 using standard in vitro electrophysiology 
to test their blocking activity.     
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Chapter 3 
Docking and Molecular Dynamics Study of TENSIN Homology Models  
using PTEN as Template 
Introduction 
At present, it is well known that the majority of cancers are a consequence of a multistep 
genetic process that includes the inactivation of tumor suppressor genes or activation of 
oncogenes.  As a consequence, apoptosis can be promoted or inhibited1. The PTEN gene is 
mutated in many advanced cancers and its name means “phosphatase homology/tensin 
homology”.2 
PTEN is a ‘dual-specificity’ phosphatase which means that substrates include both 
phosphotyrosine and phosphoserine/phosphothreonine.  An example is the vaccinia-related 
phosphatase (PDB 1VHR).  Before PTEN was discovered, no phosphatase domain was known to 
recognize both proteins and lipids3.   
The tumor suppressor function of PTEN heavily depends on its lipid phosphatase activity 
that involves dephosphorylation of the phosphate from the D3 position of phosphatidylinositol 
3,4,5-triphosphate (PIP3)4.  PTEN not only inhibits cellular migration and proliferation but also 
modulates cell growth and apoptosis5. Moreover, PTEN activity highly relates to other diseases 
such as liver diseases, diabetes, etc.6, 7. However, PTEN mechanisms of expression and function 
are not clear yet. Currently, many studies suggest that PTEN regulation can occur at the 
transcriptional level, as well as post-translationally by phosphorylation, oxidation and 
acetylation.  
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The structure is composed of two structural domains, the phosphatase (PTP’s) and C2 
domains or catalytic domain, Figure 19. C2 domains are lipid binding domains with diverse 
primary sequences8.  It is also known that some C2 domains also binds calcium and/or 
phosphotyrosine9. The PTEN structure contains the signature motif HCXXGXXR present in the 
active sites of protein tyrosine phosphatases (PTPs) which is included in the homology region of 
Tensin10. 
 
 
Figure 20 Molecular Architecture of Different Tensins and PTEN. PTP, C2, SH2 and 
PTB correspond to the respective domains whereas ZF zinc finger and AB actin binding 
domains. 
 
 Tensin is a protein localized in regions of the plasma membrane called focal adhesions, 
is widely expressed in human tissues and belongs to the group of tyrosine phosphatases (PTPs), 
which remove phosphate from phosphorylated tyrosine residues on proteins. The first tensin 
cDNA sequence was isolated from chicken in 1991, and has been predicted to have a molecular 
mass of 220 kDa11. Its structure has been characterized through different methodologies11, 12, 
indicating that it could form a dimer, even though the evidence is not yet compelling.  Tensin 
crystallographic structure is not available. Nonetheless the tensins display a high percentage of 
sequence similarity with respect to PTEN. Tensin has been classified as tensin 1, 2, 3 and 4 
according to the order of sequence characterization, the first three share PTP, C2, SH2 and PTB 
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domains in the same general locations in the gene product as Figure 20 shows, the first two 
domains at the N-terminus and the second two at the C-terminus. However Tensin 4 has no 
actin-binding region, PTP domain or C2 domain which can lead to the fact that it could compete 
with cellular targets of the other tensins via its SH2 and PTB domains {according to D. Haynie 
unpublished data}. The SH2 and PTB domains in tensin have been previously studied for 
binding activity13, 14. 
Recent articles suggest that Tensin SH2 domain is directly linked to cancer15-17; and 
although the main role of tensin in angiogenesis remains unclear, it has been discovered that 
tumor endothelial marquer 6 is tensin 315. Furthermore, it is been reported that in advanced lung 
cancer, breast cancer, and melanoma, endogenous tensin-3 helps to cell migration, anchorage-
independent growth, and tumorigenesis18.  
 The present study is focused in the building of homology models for Tensin 1, 2 and 3 C2 
and PTP domains using the PTEN X-ray crystallographic structure as a structural template. The 
validated structures were then subjected to docking simulations using molecular docking of 
druggable small molecules and molecular dynamics simulations in order to study their structures 
and function and give new insights about structural data for the subsequent use for experimental 
binding and enzymatic assays.  
 
Alignment of Tensin Sequences 
 Figure 21 shows the multiple alignments of Tensin sequences most of the substitutions 
are conservative in tensin 1, 2 and 3. The high similarity between Tensin sequences suggests that 
they emerge from gene duplication of a proto-tensin gene, which itself seems to have arisen from 
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a combination of other duplicated genes {according to D. Haynie unpublished data}.  However, 
small changes in the protein active sites could have functional implications.    
 
 
Figure 21 Alignment of Tensin 1, 2 and 3. Portions of the sequence within the active site of the 
PTP domain, showed in red squares. 
 
 The active sites in PTP domain of Tensin share high homology, the signature motif 
shared also by PTEN, show conserved glycine residues which are of great importance for the 
formation of the characteristic p-loop involved in catalysis, making the active site backbone 
more adaptable, more accommodating. Also, cysteine residues present in this binding region of 
tensin 2 and 3 are crucial for enzymatic activity through their thiol group; since in tensin 1, 
cysteine is mutated to asparigine in the active site region, it is believed that tensin 1 is 
enzymatically inactive10. However, this residue could have a significant impact on substrate 
recognition.	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Modeling Tensin  
 The primary sequences of the tensins share approximately 40% similarity with PTEN and 
this includes the PTP and C2 domains. The homology models of tensin 1, 2 and 3 were built 
using their amino acid sequences and the X-ray crystal structure of PTEN available in the PDB 
bank (code 1D5R) as the structural template19. The structure prediction was done by Prime 
Structure Predictor of the Schrodinger suite version 3.120.  The homology models were then 
stabilized by simulated annealing using Desmond: High-performance molecular dynamics 
simulations for biomolecular systems, version 3.121. The aim of simulated annealing is to get a 
more relaxed structure performing a simulation during high and low temperatures in order to 
make the structures travel from high energy potential minimum to a lower state by crossing 
barriers in the free-energy landscape. Temperature is linearly interpolated as a function of time 
between adjacent target temperatures and it is controlled by a thermostat. The simulation was 
done in 6 stages as  Table 9 shows;   the RMSD calculations during simulated annealing in 
Figure 23 show that the three tensin models tend to converge to the PTEN structure RMSD, 
which indicates that the structures energetically stabilize and are similar to the X-ray structure of 
PTEN. 
In order to determine the quality of the models, Ramachandran plots were built using the 
program Procheck21 that compares the different φ and ψ backbone dihedral angles within the 
new structures to the ones in the X-ray structures and checks if the angles are in favored regions 
that contain known angle combinations of protein secondary structures. 
Figure 23 shows that most of the aminoacids in Tensin 1 model are located within 
favored regions in the Ramachandran plot, an improvement resulted after simulated anneling 
simulation.  The majority of residues are in the alpha helix (A), beta strand (B) and left alpha 
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helix (L) allowed regions of the plot which suggests that the model is likely to be a good 
representation of the actual structure. 
 
 
Figure 22 Root Mean Square Deviations of the Homology Models of Tensin 1, 2 and 3 
compared to PTEN Structure. 
 
 
 
Table 10 Stages of the Simulated Annealing Simulation. 
 
 
  
 As explained in the previous chapter, glycine residues are shown as triangles and their 
allowable area is less restricted since contains one hydrogen in its side chain. The case of proline 
is different since its 5-membered-ring side chain shows only a very limited number of possible 
combinations of ψ and φ. Residues that are in disallowed regions are not part of the binding site. 
 
 
200 400 600 800 10000
Time (ps) 30 100 200 300 500 1000 
Temperature (K) 10 100 300 400 400 300 
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Figure 23 Ramachandran Plot of Tensin 1 Model. 23a, before simulated annealing. 23b, after 
simulated annealing. 
  
Table 11 Plot Statistics Before and After Simulated Annealing (Figure 23) 
 
 
 
 
 
 
 Figure 24 shows residues in the model aligned to PTEN residues; the amino acid type is 
conserved which indicates the secondary structure similarity between the structures. A total of 
50% of positives and 32% of identities are present in the alignment of tensin1 with PTEN, and 
were taken into account to build the model.  
 
Residues in most favored regions (A, B, L) 
Before SA AfterSA 
211 77.3% 209 78.6% 
Residues in additional allowed regions (a,b,l,p) 52 19% 45 16.9% 
Residues in generously allowed regions (~a,~b,~l,~p) 5 1.8% 9 3.4% 
Residues in disallowed regions 5 1.8% 3 1.1% 
Number of glycine residues  22 -- 22 -- 
Number of proline residues 15 -- 15 -- 
Total number of residues 305 -- 305 -- 
a b 
 45 
 
Figure 24 Sequence Alignment of Tensin 1 (T1) with PTEN 
 
 The models of Tensin 2 and 3 are similar. Figures 25 and 26, show that most of the 
residues in the structures fall in areas of allowed combination of dihedral angles also suggesting 
that the model is likely to be a good representation of the actual structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Ramachandran Plot of Tensin 2 Model. 25a, before simulated annealing. 25b, after 
simulated annealing. 
 
 Some glycine residues, shown as triangles in Ramachandran plots, are in disallowed 
regions which are acceptable since they are less restricted due to the small size of its side chain.  
The percentage of residues in disallowed regions is low and these residues are not part of the 
binding site.  Improvement after simulated annealing simulation is also shown. 
 
Figure 23 Alignment of Te i   model with PTE  
 
 
 The cases of models of Tensin 2 and 3 are similar. Figures 24 and 25, show that 
most of the residues in the structures fall in areas of allowed combination of dihedral 
angles indicating that models were built correctly.  
 
 
 
Figure 24 Ramachandran plot of tensin 2 model. 
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Table 12 Plot Statistics Before and After Simulated Annealing (Figure 25) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 Ramachandran Plot of Tensin 3 Model. 26a, before simulated annealing.  26b, after 
simulated annealing. 
 
 
 
Table 13 Plot Statistics (Figure 26)	  
  
 
 
 
 
Residues in most favored regions (A, B, L) 
Before SA After SA 
209 78.6 229 86% 
Residues in additional allowed regions (a,b,l,p) 45 16.9 25 9.4% 
Residues in generously allowed regions (~a,~b,~l,~p) 9 3.4 9 3.4% 
Residues in disallowed regions 6 1.1 6 1.1% 
Number of glycine residues  22 -- 22 -- 
Number of proline residues 15 -- 15 -- 
Total number of residues 305 -- 305 -- 
Residues in most favored regions (A, B, L) 
Before SA After SA 
208 77.6% 216 80.7% 
Residues in additional allowed regions (a,b,l,p) 48 18% 39 14.6% 
Residues in generously allowed regions (~a,~b,~l,~p) 6 2.2% 8 3.4% 
Residues in disallowed regions 6 2.2 4 1.2% 
Number of glycine residues  18 -- 18 -- 
Number of proline residues 21 -- 21 -- 
Total number of residues 308 -- 308 -- 
a b 
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 In the same way, the alignment of Tensin 2 and 3 with PTEN, Figures 27 and 28, show 
large similarity regarding amino acid type.  
 
 
Figure 27 Sequence Alignment of Tensin 2 (T2) with PTEN 
 
 In order to build the tensin 2 model, 48% positives and 29% of identities with respect to 
PTEN were considered and for tensin 3 47%  positives and 31% of identities were taken into 
account. 
 
 
Figure 28 Sequence Alignment of Tensin 3 (T3) with PTEN 
  
 Figure 29 shows the final structures of the homology models of Tensin and the structure 
from the pdb bank of PTEN. Modeling was successfully achieved since structures are similar, 
these models were used to study structure based drug screening to learn more about Tensin 
binding and function 
 
 Some glycine residues, shown as triangles in Ramachandran plots, are in 
disallowed regions which are accepted since they are less restricted due to small size of 
its side chain.  The percentage of residues in disallowed regions is low and these residues 
are not part of the binding site.  
 In the same way the alignment of Tensin 2 and 3 with PTEN, figures 26 and 27, 
show large similari y regarding amino acid type.  
 
 
Figure 26 Alignment of Tensin 2 model with PTEN 
 
 
 In rder to build tensin 2 model, 48% of positives and 29% of identities with 
resp ct to PTEN were considered and for tensin 3 47% of positives and 31% of identities 
were taken into account. 
 
 
Figure 27 Alignment of Tensin 3 model with PTEN 
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Figure 29   Final Structures of the Models. 29a, structure of tumor suppressor PTEN, PDB Code 
1D5R in Cartoon Representation. 29b, final tensin 1 model. 29c, final tensin2 model. 29d, final 
tensin 3 model.   
 
  
Tensin as a Potential Target for Drug Discovery 
 Studies suggest that tensin could link to signal transduction pathways with the 
cytoskeleton since it may perform actin-binding and phosphotyrosine-binding activities and also 
be a target for tyrosine kinases14. However, these findings are focused on the SH2 domain of 
tensin.   
a 
b 
c 
d 
 49 
 Due to the lack of structural and experimental function data of tensin PTP domain, the 
models built were evaluated with the tool SiteMap 2.2 available in the Maestro Schrodinger 
suite23 that identifies potential binding sites and predicts their druggability in three different 
stages previously explained in chapter 2.  
 Differences are shown in the maps. In the case of PTEN the known binding site of the so 
called P-loop is clearly defined. For tensin the P-loop zone, included in the homology region to 
PTEN, is also defined as possible binding site. However in the region of the C2 domain there is a 
possible site for ligand binding, which could be an artifact since no binding information is known 
about C2 domains so far. These sites were not found in the corresponding domain on PTEN 
which could give an insight with further study of the structural difference in tensins. 
 Comparing the results of the new denoted PTP domain binding sites of Tensin 1, 2 and 3 
in Table 13, indicates that binding site in tensin 2 present more volume, similar to PTEN and the 
best site score, closest to 1.   
 Most of the sitemap scores in table 13 are close to the averages proposed for Halgren23. 
Different hydrogen bonds donor and acceptor regions are shown, also areas of hydrophobic 
interactions are present which are not observed in PTEN, which is reflected in differences in the 
hydrophobic and donor/acceptor characters in table 13. The Tensin PTP domain has been shown 
to contain a binding site, diverse for each tensin model. 
 In order to compare the structures of the models and the crystal structure of the template, 
these were 3D superposed using the superposition tool of Schrödinger Maestro suite29. Binding 
sites of tensin models are similar to PTEN and share residues properties. 
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Figure 30 Sitemap Calculations.  Yellow mesh for hydrophobic maps, blue mesh for hydrogen-
bond donor maps and hydrogen-bond acceptor map as red mesh. 30a, tensin 1 model.  30b, 
tensin 2 model. 30c, tensin 3 model. 30d, PTEN. 
 
 
Table 14 Sitemap Results for PTP Domain Sites. 
Tensin 
Model SiteScore Size Exposure Enclosure 
HH 
Character 
DA 
Character 
Volume 
(Å3) 
1 0.760 94 0.72 0.697 1.064 0.534 162.239 
2 0.959 94 0.67 0.768 1.094 0.162 176.302 
3 0.840 86 0.74 0.750 1.045 1.515 101.871 
PTEN 0.930 92 0.75 0.744 0.919 0.851 174.24 
  
  
a b 
c d 
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 Figure 31-33 show that model and template have binding sites close conformations and 
that residues of tensin models have similar properties that those in PTEN.  Positively charged 
residues are shown in blue, negatively charged residues are shown in red and polar residues 
shown in cyan.  	  
 
 
Figure 31 Superposition of Model Tensin 1 and PTEN. 31a, binding sites in ribbon 
representation.  31b, residues in the binding site in licorice representation. 31c, Van der Walls 
surface of the binding sites.  31d, electrostatic surface of the binding sites. 
a b 
c d 
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  Electrostatic surface prove the existence of these charges and van der walls 
surface shows the possible sites for these interactions. The three models show marked 
similarities and slight differences in electrostatic potential surface.   
 
 
Figure 32 Superposition of Model Tensin 2 and PTEN. 32a, licorice representation of the 
residues in the binding site. 32b, superposition of binding sites ribbon representation.  32c, Van 
der Walls surface of the binding sites.  32d, electrostatic surface of the binding sites. 
 
 Models were virtual screened with the druggable compounds present in the National 
Cancer Institute (NCI) Diversity set 2, which consists of a small library, that contains about 
a b 
c d 
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2,000 synthetic small molecules known as bio-actives and selected from NCI screening bank of 
molecules. 23 
 This set was developed by the Developmental Therapeutics Program at the NIH/NCI 
from compounds in their repository. The compounds of this library, present characteristics of 
druggable molecules: rigidity, posses 5 or fewer rotatable bonds, planarity, contain one or fewer 
chiral centers and present pharmacologically desirable features.   
 
 
Figure 33 Superposition of Model Tensin 3 and PTEN. 33a, binding sites in ribbon 
representation.  33b, residues in the binding site in licorice representation. 33c, Van der Walls 
surface of the binding sites.  33d, electrostatic surface of the binding sites. 
   
a b 
c d 
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 Docking studies have been performed using GLIDE 5.8 of Schrodinger25, which 
performs high-throughput virtual screening of potential ligands based on binding mode and 
affinity for a given receptor molecule.  The GlideScore includes the following terms: 
GScore = 0.05*vdW + 0.15*Coul + Lipo + Hbond + Metal + Rewards + RotB + Site 
 Where, vdW is Van der Waals energy, Coul is Coulomb energy, Lipo is the lipophilic 
term for hydrophobic interactions, HBond is the hydrogen-bonding term, Metal is the metal-
binding term, Rewards are the rewards and penalties for: buried polar groups, hydrophobic 
enclosure, correlated hydrogen bonds and amide twists; RotB is the penalty for freezing rotatable 
bonds and Site is for polar interactions in the active25.  
 Table 14 shows the Glide scores for the tensin models and PTEN. Matches are observed 
and compound number 78623 was a common compound docked in PTEN, Tensin 2 and 3; on 
the other hand, compound number 156939 was a common compound for the three models of 
Tensin. Differences in the lipophilic scores regarding hydrophobic interactions are small between 
models and PTEN the same in the case of the hydrogen bonding scores. However, van der Walls 
interactions energy term shows differences in the case of tensin 3 which involves a more 
favorable site for these interactions.  Coulomb energy term fluctuates among the different models 
which could be due to the presence of several charged residues in binding sites. 
 Figure 34 shows some of the possible poses of the resultant small molecular probes that 
could be potential drugs and the main interactions present with the residues in the binding sites. 
Interactions mostly involve the lysines and glycines in P-loop.  Cases of Tensin 3 and PTEN are 
more similar including glycines in the interactions. 
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Figure 34 Interactions of the Residues in the Binding Site of Tensin1 (a), Tensin2 (b), Tensin 3 
(c) and PTEN with Potential Drugs. Positively charged residues in blue, negatively charged 
residues in red, hydrophobic residues in green, glycines in gray. 
  
 In order to prove stability of the complexes, each one of the models of tensin  coordinates 
of the complexes were prepared using VMD program (Visual Molecular Dynamics version 
1.9.1)26 for molecular Dynamics Simulation.  Simulations were performed with the NAMD27 and 
CHARMM force fields28. Periodic boundary conditions were used placing the initial structure in 
an equilibrated water box. Cl- ions were added instead of water molecules at the most positive 
electrical potential in order to create a neutral and more realistic box. 
 
a b 
c d 
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Table 14 Binding Scores of PTEN and Models of Tensin 1, 2 and 3 (Kcal/mol).  
Receptor C number G Score lipo Hbond Evdw eCoul 
PTEN	  
78623	   -9.721	   -1.545	   -0.883	   -21.984	   -26.985	  
78623	   -9.272	   -1.493	   -0.826	   -22.597	   -25.627	  
36162	   -8.462	   -2.359	   -0.718	   -28.171	   -12.670	  
379099	   -7.798	   -1.376	   -1.156	   -22.298	   -22.023	  
38743	   -7.601	   -1.488	   -0.904	   -27.553	   -18.106	  
117922	   -7.556	   -2.082	   -0.430	   -18.503	   -22.058	  
128281	   -7.511	   -0.808	   -0.946	   -19.720	   -16.895	  
122131	   -7.487	   -1.063	   -1.275	   -18.274	   -20.546	  
Tensin 1 
7606 -7.189  -1.369 -0.847 -19.216 -15.190 
35076 -7.155  -0.471 -0.326 -20.841 -19.456 
43546 -7.062  -1.199 -0.405 -17.174 -16.712 
156939 -6.973  -0.944 -0.740 -19.875 -16.210 
34875 -6.928  -1.312 -0.996 -24.388 -10.467 
16736 -6.910  -0.902 -0.842 -31.554 -5.670 
659449 -6.891  -1.158 -0.641 -22.558 -19.152 
93945 -6.887  -0.976 -0.496 -28.198 -15.549 
Tensin 2 
107022 -7.128  -0.422 -0.307 -13.094 -27.912 
156939 -6.791  -0.308 -0.730 -19.649 -21.602 
7606 -6.568  -0.197 -0.935 -21.370 -8.009 
36914 -6.473  -0.423 -0.466 -19.204 -8.297 
14771 -6.387  -0.436 -0.552 -18.293 -9.977 
659434 -6.362  -0.519 -0.823 -20.091 -10.116 
19108 -6.294  -0.553 -0.974 -27.094 -6.796 
78623 -6.243  -0.157 -0.841 -19.486 -14.401 
Tensin 3 
	  
156939  -7.768  -1.527 -0.922 -28.811 -18.248 
35676  -7.424  -1.268 -0.720 -30.831 -14.190 
36586  -7.350  -0.984 -0.946 -33.977 -13.154 
270063 -7.236  -0.904 -0.958 -35.263 -12.033 
107022  -7.153  -1.688 -0.679 -36.319 -9.566 
34875  -7.137  -2.446 -0.436 -38.928 -19.900 
78623  -6.999  -2.237 -0.616 -33.529 -11.003 
38743  -6.971  -1.625 -0.619 -21.940 -12.951 
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The minimization, heating and equilibration of the system were completed during 
1100ps. The system was minimized, then equilibrated at constant volume for 400ps. A standard 
MD trajectory 2ns long, at constant pressure and temperature, was performed. The integration 
time step was 2fs, Van der Waals interactions were calculated every step (2fs) while 
electrostatics interactions were calculated every other step (PME every 4fs), using the multiple 
time step method employed by NAMD. The Particle Ewald Mesh (PME) summation for long 
range electrostatic interactions was used. 
 Figure 35 shows the results of the RMSD calculations of the molecular dynamics 
simulations of the complexes between Tensin 1, 2 and 3 models with the top docking pose 
corresponding to the best binding score. Stability of the complexes is achieved after half of the 
simulation has elapsed. The complexes converged in all cases and ligand-receptor interactions 
were then evaluated for the matching cases.  
 
Figure 35 RMSD during MD Simulation of Tensin Complexes 
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 Interactions of PTEN, tensin 2 and tensin 3 with compound number 78623 are in Figure 
36. They were drawn using the interaction map tool of Maestro suite of Schrodinger28.  The 
compound 78623 with molecular formula C13H12N2O6 and the nomenclature 5-amino-2-(5-
hydroxy-1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-5-oxopentanoic acid, presents functional 
groups with diverse characteristics for drug discovery.   
  
  
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 36 Ligand-Receptor Interactions Diagram for Compound 78623. 36a, tensin 2 model.  
36b, tensin 3 model. 36c, PTEN. 
a b 
c 
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 The phenolate ion shows H-bonds and ionic interactions with positively charged residues 
in tensin 2 and 3, also the ring present some exposure to the solvent.  In the case of PTEN the 
interactions of this portion of the molecule present H-bonds with hydrophobic and polar residues 
in the binding site.  Phenols are relatively soluble molecules that are relatively easily 
deprotonated and  somewhat reactive toward oxidation ; however phenol substructures are part 
of numerous drugs such as antipyretics, steroids and analogs of catecholamines30.  
 A cyclic imide is in the core of the molecule, presenting ionic interactions with positively 
charged residues in the binding site of PTEN. In the case of tensin 2 and 3 these interactions are 
less marked including one Lys residue in binding region. Most imide-containing drugs are cyclic 
imides which are more stable than open-chain imides28.  Imides react with nuclophiles faster than 
amides, are soluble in polar media since are highly polar.  Two more groups are present in the 
proposed molecule, an amide group that shows ionic interactions and H-bonds with negatively 
charged residues in PTEN and Tensin binding sites and a carboxyl group that presents also ionic 
interactions and H-bonds with positively charged residues in the binding site of all the structures. 
Amides are a functional group commonly present in living organisms. In that way, unnatural 
amides are sufficiently stable to serve as oral drugs and quick enzymatic hydrolysis rarely 
occurs30. The case of the carboxyl group is similar since these are found deprotonated and 
negatively charged in most parts of the body.  Carboxyl group constitute an important 
pharmacophore of drugs like: fibrates, statins, nonsteroidal ant-inflammatory drugs (NSAIDs), 
angiotensin-converting enzyme (ACE) inhibitors, and β-lactam and quinolone antibacterials. 
Although usually reasonably well absorbed, carboxyl groups have low volumes of distribution 
and few cross the blood-brain barrier (bbb)30. 
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 Figure 36 shows the interaction diagram of the compound 156939 with Tensin 1, 2 and 3 
models. Compound number 156939 of molecular formula C15H10N2O6 and the nomenclature 
methyl 6-formyl-4,7-dihydroxy-9-oxo-5H-phenazine-1-carboxylate, is also known as 
Lomofungin or Lomondomycin an antibiotic used in the 1970s for fungal infections. Diverse 
functional groups are present interacting with tensin 1, 2 and 3 models30.  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37 Ligand-Receptor Interactions Diagram for Compound 156939. 37a, tensin 1 model.  
37b, tensin 2 model. 37c, tensin 3 model. 
   
a 
b 
c 
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  Methyl paraben or the methyl ester of p-hydroxybenzoic acid interacts with positively 
charged residues in the binding pocket of Tensin 1 and 3 through H-bonds. The orientation of the 
possible inhibitor in Tensin 3 makes this portion of the molecule the most interacting one, 
presenting hydrophobic interactions with several residues in the binding pocket.  In tensin 1 and 
2 this portion of the molecule is exposed to the solvent.  Carboxylic acid esters are often used as 
prodrugs for carboxylic acids, phenols or alcohols due to their metabolic lability, they are more 
lipophilic than carboxylic acids30.     
 Moreover, the 2, 4-Dihydroxybenzaldehyde is the portion of the molecule that interacts 
with tensin 1 and 2. It forms H-bonds with positively charged residues, acting as H-acceptor, in 
the binding pocket as well as with negatively charged residues acting as H-donor. Ionic 
interactions are also present with tensin 1 and 2. In the case of tensin 3 is exposed to the solvent 
although it forms 2 H-bonds with a polar residue. Aldehydes are highly electrophilic; the formyl 
group could react quickly with a nucleophile and also it can be oxidized to an acid or reduced to 
an alcohol, however cyclic Aldehydes are sufficiently stable and common substructures for many 
drugs30. 
 A pyrazine molecule that presents just some polar and hydrophobic interactions is the 
core of the proposed inhibitor molecule. Even thought the three models of tensin bind the same 
compound of the NCI diversity set II, tensin 1 and 2 present similarities when binding this 
molecule but tensin 3 present different interactions and orientation, indicating differences in 
binding pocket. 
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Conclusions and Future Directions 
 Models of Tensin 1, 2 and 3 were built and represent potential tertiary structures for the 
Tensin molecule, similar to PTEN.  
 Binding sites of Tensin 1, 2 and 3 are represented hydrophobic and hydrophilic maps 
further divided into H-donor and H-acceptor maps. 
 Potential inhibitors for Tensin have been identified by docking studies and resulting 
molecules have shown selectivity for Tensin. 
 Future directions involve the docking of phosphotyrosine and phosphoserine peptides, 
known to bond PTEN experimentally, in Tensin using protein-protein docking methods and for 
comparison with the results of enzymatic assays in Dr. Haynie research laboratory.  Results of 
virtual screening will be used to guide high-throughput screening for inhibitors of phosphatase 
activity that are selective for PTEN and the various tensins, taking advantage of the structural 
similarity between well known PTEN and tensins. 
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Chapter 4 
Molecular Dynamics Simulations of Deoxy and Carboxy bjFixLH in Crystal and Solution: 
Intrinsic Dynamics Affects the Behavior of the Ligand after Dissociation 
 
Introduction 
Heme-based sensors are ligand-binding proteins that contain a regulatory heme-binding 
domain or subunit that regulates the closest transmitter region of the same protein. Signal 
transducing proteins guide adaptive responses to variations in concentrations of diatomic gases 
such as O2, CO or NO, that are currently perceived as physiological messengers1,2. The rhizobial 
FixL/FixJ two-component system is a model of biological oxygen sensors, main function consist 
of detecting low O2 tensions in order to regulate the expression of the genes responsible for 
nitrogen fixation in the anaerobic state within plant root nodules3.  In FixL, the N-terminal 
consists of a heme-sensory domain whose sequence and tertiary structure makes it a member of 
the heme-PAS family, whereas, the C-terminal domain belongs to the family of histidine kinases 
and its activity is controlled by the heme-sensory PAS domain4.  At low O2 tensions, the heme of 
the PAS domain is unliganded; the kinase undergoes autophosphorylation and then transfers this 
phosphoryl group to its partner, the DNA-binding response regulator FixJ to express the fixK and 
nifA genes. At high O2 tensions the heme is oxygen bound and the kinase activity is suppressed5.  
 The mechanism of ligand recognition and signal transduction of the isolated heme 
domain of FixL, derived from Bradyrhizobium japonicum denoted as bjFixLH (Figure 33) has 
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been widely investigated by crystallographic studies6-10.  The binding of strong field ligands to 
bjFixLH leads to  the conformational change of the heme iron that causes motion in other parts 
of the protein that regulate the activity of the  histidine kinase6, 7.  Oxygen or cyanide binding to 
the bjFixL heme domain involves a change in the heme stereochemistry that produces 
conformational changes in the FG loop and in residues distal to the heme in the Hβ and Iβ strands 
of the core β sheet of the PAS domain8, 9. The structure of bjFixLH bound to nitric oxide, which 
is a potential product of denitrification by Rhizobia11, gives the insight of a structural 
intermediate in the heme-driven conformational change8. Carbon monoxide is a weaker inhibitor 
of the kinase activity than oxygen. The structural conformation of the FG loop in the CO-bound 
protein is different compared to the O2- and CN-bound structures but similar structural changes 
are observed in the Hβ and Iβ strands12. Thus, diatomic ligands are divided into strong and weak 
inhibitors: O2 and CN- act as strong inhibitors and CO and NO as weak inhibitors. Also, it has 
been shown that upon ligand binding, the heme flats driving a change in the position of the heme 
propionates6-12.  A salt bridge between the Arginine residue at position 220 and the propionate 7 
is present in the deoxy bjFixLH structure13. As a consequence, the shift in the position of the 
heme propionates reduces the strength of this bond and the Arg220 residue moves into the heme 
pocket forming a hydrogen bond with the ligand (O2, CN-), eventually inducing the structural 
reorganization responsible for kinase inactivation13, 14. In the CO-bound FixL structure, an 
absence of interaction between the CO ligand and the Arg220 has been reported15, 16, thus, this 
residue remains outside of the heme distal pocket and pointing toward the heme propionate 7 
group.  Another residue that has been related to Arg220 is Arg206, located at the Fα helix and is 
considered an important residue in the structural changes related to the signaling mechanism 
because it compensates for the negatively charged propionate 7 upon loss of Arg220 in oxy 
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structures8, 9. It also becomes bound to HP6 by a salt bridge in CN- structures7; on the other hand, 
in a previous experimental study of bjFixLH16, a bond between the side chain Arg206 and 
Asp212 has been reported in the deoxy structure, whereas, it becomes disordered after binding of 
CO. 
 
 
Figure 38 a, Molecular Representation of the Structure of the CO Bound bjFixLH (PDB Code 
1lsv). Secondary structure regions within the protein are identified. 33b, CPK graphical 
representation of the CO bound bjFixLH heme pocket. Several groups and residues involved in 
structural changes are denoted. 
 
Recent experiments obtained after CO photolysis and recombination in bjFixLH using 
time-resolved Laue X-ray crystallography shows important conformational changes occurring in 
the protein as a consequence of the relaxation of the steric interactions between the bound ligand 
and the side chains of residues around it, and also the change in heme stereochemistry has been 
reported. The experiments also showed how these structural changes fully reverse as CO rebinds 
to the heme16, 17.  
	  
	  
	  
a b 
GH  Loop 
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 In the present study, molecular dynamic simulations of the CO-bound and CO-unbound 
structures of the bjFixLH were performed, modifying the parameters of heme ligation, to 
investigate the ligand behavior after CO dissociation as well as the conformations of the protein 
before and after ligand dissociation. Simulations were computed in two different environments: a 
crystal simulation of a rhombohedral cell containing 18 molecules (Figure 34) and a simulation 
of one protein molecule in aqueous solution, with the aim of compare them to experimental 
results reported in X-ray time resolved crystallographic studies of this protein17-19.  Different 
features after CO dissociation were observed in the different simulation environments. 
Conformational changes observed in previous experiments by liganded and unliganded structures 
of this protein are observed in our simulations but with an important dependence on the location 
of the ligand after bond dissociation. 
 
CO Dynamics 
Calculations of the distance between the ligand and the heme iron following 
dissociation show that the ligand escapes from the heme pocket just 0.13 ns ± 0.04 after the CO 
bond is broken in the solution simulations. These results were similar in the three simulations of 
the protein performed in the water box. By that time some characteristic structural changes due 
to relaxation to the deoxy state can be observed but due to the fast escape the CO behavior inside 
the heme pocket was not described with detail. 
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Figure 39 Configuration of the Unit Cell of the CO Bound bjFixLH. Eighteen H32 symmetry-
related protein molecules are present. Molecules in blue represent proteins where the CO remains 
inside the protein cavity during the complete CO-unbound simulation. 
 
 This behavior was different in the MD simulations of the crystal, where 18 proteins are 
present in the unit cell. After the bond breaking, the CO stayed within the protein cavity for eight 
of the protein molecules during the entire simulation (blue molecules in (Figure 34) whereas for 
four other protein molecules the ligand escapes a few fractions of nanosecond after the Fe-CO 
bond is removed as in the solution simulations. For the rest of the protein molecules, the CO 
escape is observed in between 1 to 10 ns after the bond breaking of the ligand (Figure 35).  Our 
results show that ~50% of the ligand molecules escape to the solvent at different times in the 
CO-unbound crystal simulation.  
To study the behavior of the ligand inside the cavity for the eight molecules in which 
the CO stays in the binding pocket, analysis of the vector connecting the heme iron atom and the 
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ligand was performed. The CO molecule motion was divided into vertical and horizontal 
displacements of this vector with respect to the heme plane 
 
 
Figure 40 Probability Distribution of CO Remaining near the Heme Pocket during the 
Crystal MD Simulations. The CO-Fe bond is broken at 10 ns in our simulations. 
 
 Figure 36 shows the average of these displacements for the 8 protein molecules. The 
horizontal displacement and fluctuations are greater than the vertical projection. This shows that 
the unbound ligand is close to the heme and can interact with some hydrophobic side chains that 
point toward the heme: Ile215, Val222, Met234, Leu236 and Ile238.  
 
Structural Changes 
The different conformational changes that occur in the protein following the CO 
dissociation were studied to compare our simulations to the results reported in previous 
experimental work where the bond between the heme iron and the ligand is removed by 
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photolysis17. We used vector analysis and determination of distances between different residues 
involved in these motions during the simulations. 
 
 
Figure 41 Displacement of the CO Molecule after Bond Dissociation for the Protein Molecules 
in the Crystal Simulations where the CO Remains in the Binding Pocket. Thin line represents the 
average horizontal projection of Fe-CO vector onto Fe-CH* vector in the heme plane, Bold line 
represents the average vertical projection of Fe-CO vector onto a vector perpendicular to the 
heme plane. 
 
  
Some of the structural changes involve motions of the side chains of amino acids within 
the protein that are driven by steric interactions with the ligand. Other motions require the 
movement of backbone atoms producing longer-range conformational changes. The protein 
regions with more notable conformational changes during the simulations are the Hß and Iß 
strands, the FG loop, the heme group, and the Cα and Fα helices (Figure 38). 
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Hβ and Iβ Strands  
It has been reported that Leu236 located at the Hß strand, must vacate the ligand binding 
pocket to accommodate the bound CO16. This involves the shift of the main chain atoms of 
Leu236 away from the CO along the Hß strand toward the C-terminus16, 17.   
Distance calculations between the side chain of Leu236 and the heme iron show that 
there is an average decrease from 7.5 Å to 6.5 Å at the time the CO-Fe bond breaking occurs, 
similarly, in the case of Ile238 a decrease was observed from 8.5 Å to 7.25 Å, which is indicative 
of the movement of the side chains toward the place where the ligand was present. This distance 
reduction is evident in the solution simulations as well as for the four proteins in the crystal 
simulations for which the ligand escapes immediately from the heme pocket after CO 
dissociation. During the first 10 ns of the run (in which the ligand was bound), that distance is 
longer for the side chains of both amino acids, indicating that these residues vacate the place 
where CO is located, due to steric interactions present among themselves.  
 In the case of the protein molecules where the CO remains in the binding pocket after 
bond breaking that distance decreases less (about 0.5 Å), due to the presence of the ligand inside 
the protein cavity.  
 Displacement of the Iß strand after release of the ligand is driven by the motion of the side 
chain of Leu23617.  Hydrogen bonds between Leu236 main chain atoms and the Iß strand residues 
Phe252 and Val253, are evident during all the simulations before and after ligand dissociation. 
Similarly, Arg254 side chain moves in our simulations as a consequence of a reported structural 
domino effect17. But the backbone locations of these amino acids remain mostly unaffected after 
ligand dissociation. 
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Heme 
Displacement of the heme, after the relaxation of the steric hindrance present in the CO-
bound heme and the side chain of Leu236, has also been reported17. This causes the motion of the 
heme away from FG loop.  
 Figure 37 displays the distribution of the distance between the centers of mass of 
the FG loop and the heme group. The figure shows that when the CO is bound to the iron atom 
this distance distribution is mostly unimodal and centered around 9.2 Å. The distribution is 
broader when the CO remains in the cavity after the CO-Fe breaking event. It also shows a shift 
of the heme away from the FG loop. Differently, when the ligand escapes the distribution 
becomes bimodal with the heme and FG loop coming closer together.  The distance between the 
heme and the side chain of Phe176 in the Cα helix is a probe of the approach of the heme to the 
Cα helix. In the cases where the heme is moving away from the FG loop this distance decreases 
from 7.25 Å to 3.97 Å. 
 Fα helix motion is caused by heme doming and also the motion of the iron out of 
movement of the heme plane17. The RMSD of the Fα helix main chain atoms shows an average 
increase from 0.43 Å to 1.74 Å during the last 10 ns of the simulation when the CO-Fe bond is 
broken and the heme changes its geometry. Heme propionates also show small displacements 
during our simulations. 
 For HP6 the RMSD reaches 1.3Å after the breaking of the CO-Fe bond whereas for HP7 
the RMSD fluctuates between two conformations (with RMSD of 0.25 and 1.1 Å) during the 
entire simulation including bound and unbound ligand. These variations correspond to the 
motion of propionates as a consequence of the heme doming. 
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Figure 42 Frequency Distribution of the Distance Separating the Centers of Mass of the FG 
Loop and the Heme Group. The solid line represents the distribution of the data in the first 10 ns 
(bound ligand). The dashed and dot lines represent the distance distribution for the proteins when 
the ligand remains in the cavity and when it escapes, respectively. All the protein conformations 
in solution and crystal simulations were included. 
 
FG loop 
The FG loop region extends from residue Ser211 to residue Ile215, and its motion after 
CO dissociation has been considered a consequence of the heme doming and the motion of the 
heme propionate groups, together with the steric interaction between Ile215 and the ligand16. 
During our simulations, the motion of the propionate groups drives the motion of the FG loop 
through hydrogen bonds formed between these groups and residues in the loop. Specifically, 
HP6 forms H-bonds with His214, whereas, HP7 forms H-bonds with Ile215 and Ile216 and a salt 
bridge with His214 during the entire simulation. These H-bonds are unaffected by the presence 
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or absence of the bond between CO and the iron atom. After CO dissociation, the distance 
between Ile215 and the ligand shows an average decrease from 6.63Å to 3.27Å in the case of the 
proteins where the ligand remains in the cavity. This indicates an approach of the ligand to this 
hydrophobic residue suggesting steric interactions between them that lead to the FG loop motion. 
This ligand motion is related to the horizontal displacement observed in Figure 36. 
 Another of the reported structural changes16 is the motion of the FG loop (residues 
His213 to Ile215) towards the place where the heme stays after the removal of the CO-Fe bond 
with a corresponding distance increase between residues Ile216 to Ile218 that belong to the Gβ 
strand, and the heme pocket. Distance calculations between the residues that belong to the center 
of the FG loop (His213 to Ile215) and the heme show a decrease of 1.23Å, in cases where the 
ligand escapes from the cavity after bond breaking. The opposite occurs for the eight proteins in 
the crystal where the ligand remains inside the cavity during the entire simulation with a distance 
increase of 2.16Å. Moreover, the distance from residues Ile216, Ile217 and Ile218 to the heme 
increases by an average of 1.58Å, for the cases where the CO escapes from the heme pocket. But 
the same distance decreases slightly (an average of 0.55Å) for the rest of the proteins.  
 
Arg220 and Arg206. 
Arg220 belongs to the Gß strand and it is considered an important residue in bjFixLH 
kinase inactivation mechanism since it stabilizes strong field ligands (O2, CN-), upon ligation by 
hydrogen bonds7, 8.  
 A salt bridge between HP7 O1A and the distal residue Arg220 has been reported as 
characteristic of the CO structure regardless the spin state of the heme iron14, 15; these studies 
have shown that this salt bridge remains intact in both, the CO-bound and the CO-unbound 
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structures15, 16.  However, our results show that this interaction is changing during the duration of 
the simulations.  Figure 38 shows that when the CO-Fe bond is present the distance distribution 
between the O1A of HP7 and NH2 of Arg220 is mostly centered at 3.2Å, which means the salt 
bridge is formed. Smaller peaks around 4.8Å indicate the HP7-Arg220 distance oscillates over 
time, including larger distances where the salt bridge is not formed. There is a broader 
distribution of distances for proteins in which the CO will escape from the protein cavity after 
CO dissociation that indicates that the salt bridge was breaking more often for these molecules. 
On the other hand after the CO-Fe bond breaking event, in proteins where the ligand stays inside 
the cavity the average distance distribution still has a large peak around 3.2Å. The drastic 
increase in the distance between O1A and the Arg220 residue in proteins where the ligand 
escapes to the solvent is correlated to the CO escape, so this interaction could be coupled to the 
onset of the ligand escape. 
 Arg206 motion has been related to structural changes in Arg220. Arg206 is known to 
compensate HP7 when its salt bridge with Arg220 is not present in O2-bound structures8. Still, it 
has been reported that Arg206 is bound to HP6 in CN--bound structures7, and its position is more 
disordered in CO-bound structures which points to a difference between these the different 
ligand-bound structures regarding Arg220 behavior16. Distance calculations show a salt bridge 
between Arg206 and HP6 during the CO-bound structure runs, which suggests a similarity to a 
strong field ligand in bjFixL, whereas another salt bridge between Arg206 NH1 and HP7 O2A is 
formed during the CO-unbound structure simulation just for proteins where the ligand stays 
within the cavity which implies that Arg206 compensates HP7 similarly to O2 bound structures.  
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Figure 43 Average Frequency Distribution of the Distance between O1A of HP7 and NH2 in the 
Basic Residue Arg220 during the Simulation. Salt bridges are within the cutoff distance 
(minimal distance) of 3.2Å.  Solid and dotted lines represent the first 10ns of the simulation (CO 
bound structure) while dashed lines represent the run time period from 10 to 20 ns (unbound 
structure). Each distribution is normalized. 
 
  
 It has also been shown that there is a salt bridge and hydrogen bonding between Asp212 
and Arg206, characteristic of deoxy structures16.  Our simulations show that when the CO-Fe 
bond is present, the Arg206-Asp212 salt bridge is forming intermittently and when the CO-Fe 
bond is removed this salt bridge is present just for the proteins where the CO escapes. The salt 
bridge is broken permanently when the ligand remains within the cavity.  The interaction 
between these two residues indicates that FixL relaxes to the deoxy state when CO escapes from 
the cavity. Therefore Arg206 interactions depends on ligand behavior  
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Relaxation to the Deoxy State 
Backbone RMSD between the deoxy crystal structure and the conformations sampled in 
our simulations are plotted over time in Figure 39.  These plots show that, during the CO-bound 
simulation (below 10 ns), there are differences between the proteins configurations; these are 
consequence of fluctuations involving mostly motions of the N-terminal helix. In the case of the 
CO-unbound simulations (after 10 ns), when the CO remains in the cavity the proteins deviate 
more from the deoxy configuration. For proteins with CO escaping events the configurations 
approach the deoxy structure as expected.  
 
Structural Changes and Comparison with Experiments  
Our crystal simulation results showed that for about 50% of the proteins within the unit 
cell the ligand stays within the protein cavity presenting horizontal displacements with respect to 
the heme location that lead to steric interactions with hydrophobic residues near the heme. This 
suggests that rebinding features could occur for these proteins (in agreement with experiment) 16 
while structural relaxation to the deoxy state is observed in proteins where the ligand escapes 
completely from the protein framework. 
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Figure 44. Backbone RMSD between the Deoxy Structure (PDB entry 1XJ2 28) and the 
Conformations Sampled in all the Simulations Plotted over Time.  The solid line represents the 
results for proteins where the ligand remains in the cavity and the dotted line represents the 
results for protein where the ligand escapes. The average standard deviation for both curves is  ± 
0.39, so deviations of the two curves after bond breaking (10 ns time) are slightly above the 
statistical errors. 
 
 The side chain of Leu236 has been proposed as a ligand sensing moiety since its motion 
toward the hole vacated by CO has been related to the relaxation to the deoxy state whereas the 
same residue moves away in the presence of a bound ligand16, 17. Similar changes on the side 
chains of Leu236 and Ile238 were observed during our simulations. The side chains of the 
residues are closer to the heme iron as the ligand escapes the binding pocket, which points out 
the release of their steric interaction with the CO when the ligand is bound to the heme. 
However, the propagation of structural changes as a consequence of these motions, through 
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hydrogen bonds with residues in the Iß strand is not observed during the duration of our 
simulations in contrast to experimental observations17. 
 Lateral displacement of the heme group was observed during the simulations (Figure 36) 
in partial agreement with experimental results17. But we observed that this motion depends on the 
location of the CO after the dissociation event. When the ligand remains inside the binding 
pocket, the heme moves away from the FG loop and approaches the Cα helix in agreement with 
the experimental observations. These changes occur due to steric interactions between the 
hydrophobic residue Ile215 in the FG loop and the dissociated ligand. The opposite motions 
occur when CO escapes, the absence of these interactions after CO escape makes the heme and 
the FG loop approach but only slightly (higher peak in the dotted line distribution of  Figure 37). 
Averaging the two opposite motions results in a slight lateral increase of the separation between 
the heme group and the FG loop as observed in the experiment.   
 Heme doming and the movement of the iron out of the porphyrin plane after the breaking 
of the CO-Fe bond in our simulations lead to the motion of the Fα helix through His200 in 
agreement to crystallographic studies17. Furthermore, the relative position of the heme propionate 
6 shows variations after ligand dissociation that can be related to heme doming whereas heme 
propionate 7 shows smaller fluctuations during all the simulations that are not affected by the 
dissociation of the CO. The continuing fluctuations of propionate 7 make the salt bridge between 
Arg220 and HP7, characteristic of deoxy and CO-bound structures, break often.  
 FG loop motion is correlated to heme propionates displacements, due to hydrogen bonds 
and salt bridges formed between residues Pro213, His214, Ile215 and Ile216 in the loop and HP6 
and HP7. Also, the simulations show an important dependence of the FG loop movement on the 
steric interactions with the ligand. From our simulations, when the ligand escapes from the 
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protein cavity after dissociation the central portion of the loop moves toward the heme while the 
portion of residues Ile216 to Ile218 moves away from the heme as a correlated movement. These 
motions were observed in the experiments17. However, motion in the opposite direction occurs 
when the ligand remains inside the cavity in our simulations. This motion is not reflected in the 
same experiments. The steric interactions between the ligand and Ile215 drive the motion of the 
FG loop central portion away from the heme. So, when the ligand stays close to the heme pocket 
is inside a “cage” formed by the hydrophobic residues Ile215, Val222, Met234, Leu236 and 
Ile238, which keep it there, as it is shown in Figure 40. 
 
 
 
Figure 45 Representation of the Cage-Like Shape Surrounding the CO Ligand of a bjFixLH Protein 
Molecule in Crystal Structure. 
 
 It also has been shown that there is a relationship between Arg220 and Arg206 dynamics 
for O2 bound bjFixL structures8.  However, this correlation has not been observed in the case of 
the CO bound structure16. In agreement to previous experimental results7, 16, during the CO-bound 
structure simulations Arg220-HP7 and Arg206-HP6 salt bridges are present.  However, our 
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  Leu236	  Ile238	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simulations display different behaviors after dissociation of CO: ligand escape causes the break 
of the salt bridge between Arg220 and HP7 whereas Arg206 is interacting with Asp212 by 
hydrogen bond, which constitutes a deoxy bjFixL structural feature. When the ligand stays 
within the cavity both salt bridges Arg220-HP7 and Arg206-HP7 are forming simultaneously 
that indicates that these changes are not mutually exclusive. These observations suggest that the 
escape of CO could be related to the increase in distance between Arg220 and O2A in HP7 or the 
break of this salt bridge. This makes Arg220 to act as a “gate” in the protein cavity.  
 Structural changes that have been experimentally demonstrated are observed during our 
simulations with important differences depending on the location of the CO after its dissociation. 
The fact that the ligand presents different behaviors affects the structural changes observed in the 
proteins.   
 
Crystal Unit Cell Deformation 
Simulations in the crystal cell using harmonic constraints applied to the protein backbone 
were also performed. For these simulations ligand behavior results were similar as before and the 
reported structural changes in the protein side chains driven by steric interactions with the ligand, 
occurred as well. These similarities indicate that the crystal deformation is not caused by changes 
in the shapes of the protein molecules but rather by a change in the packing and water 
distribution within the crystal. 
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PCA Analysis 
PCA result in a set of modes called eigenvectors that represent non-redundant motions in 
an MD simulation for a molecule in particular. Every PCA mode is associated with an 
eigenvalue; which is defined as the amplitude of fluctuations along that particular mode, each 
subsequent mode represents the following largest principal axis of atomic fluctuations 
orthogonal to the previous axes20, 21.  PCA analysis was done on the trajectory data using the 
alpha carbons of each of the 117 residues of the 18 FixL proteins in the unit cell. The results 
yielded 3N total modes, where N is the total number of atoms used giving a total of 351 modes 
per protein. Using the eigenvalues of the covariance matrix, the calculation of the contribution of 
a mode to the total conformational variance was done for our simulation. For all the proteins in 
the crystal structure the first mode of motion includes the largest percent of atomic fluctuations 
(>96%) represented in the covariance matrix during the CO bound simulations. A small residual 
contribution of the second mode also was observed and the rest of the modes slightly contribute 
to each residue fluctuations. Figure 41 shows the FixLH average residue fluctuations when the 
CO is bound to the proteins along the first PC mode. The results are divided in two dependent on 
the final outcome of the ligand after the Fe-CO bond breaking: fluctuations for proteins in which 
the ligand remains within the heme pocket and proteins in which the ligand escapes from the 
cavity. In the case of the proteins where the ligand stays within the cavity after bond breaking, 
variations at residue His162 are observed, also fluctuations around the Fα helix (Ile190 to 
Thr210) are important in this case, as well as the large fluctuations observed for residue Asp228 
and in the region of the GH loop (~Ser243).  Fluctuations are different in the case of the proteins 
where the ligand escapes from the heme pocket. The figure shows fluctuations in the region of 
the Cα helix (Thr170 to Phe176), also some peaks around the EF loop (Met192 to Asp196). 
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Fluctuations within the regions that include the FG loop and the Gβ strand (Thr210 to Lys225), 
are also observed. Large fluctuations are observed around residues Leu236 to Thr250 that 
corresponds to some residues of the H and I β strands. The region from 255 to 270 corresponds 
to the helix at the end of the protein, which is fluctuating indistinctly during all simulations 
without any relation to the ligand dynamics. Variations of intrinsic motions of FixL before the 
bond-breaking event determines the fate of the ligand after bond rupture. If the residues that 
surround the CO are less mobile before the breaking then the ligand has a larger probability to 
stay within the heme pocket. 
 
	  
Figure 46 FixLH Average Residue Fluctuations during the CO Bound Simulation of the Proteins 
along the PC1. The data is separated in two (CO escapes or stays) according to the ligand 
behavior after bond breaking. For most residues the fluctuations are larger if the final outcome 
after bond breaking is for the ligand to escape. 
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Ligand Dynamics inside Pocket 
Figure 42 shows CO local dynamics within the heme pocket with panels a, b and c 
displaying the path of the center of mass of the ligand during the CO unbound simulation22. 
Three different scenarios are observed. In the scenario C1 (panels a,d) the CO motion is around 
the methine bridge B (CHB) of the heme and it shows contacts between the ligand and the Gβ 
and Hβ strands. In the scenario C2 (panels b,e) the ligand remains close to methine bridge A 
(CHA) and presents contacts with the Fα helix, the FG loop and the Gβ strand. In the scenario C3 
(panels c,f) the ligand moves near the methine bridge C (CHC) and shows contacts with Hβ and 
Iβ strands. Therefore three different possible cavities are present inside the heme pocket 
according to our simulations. It has been shown through picoseconds mid-infrared spectroscopy 
that a cavity within the core of PAS domain adjacent to the heme is present, close to the CHC 
methine bridge, which is in agreement with the scenario C323. Probabilities of the ligand 
remaining in each cavity are shown in Figure 43. In the figure we are using data for all the 
proteins in the crystal structure simulation in which the ligand stays closer to the heme group 
immediately after bond breaking. Cavities C1 and C2 present a lower probability of the ligand 
remaining closer to them than cavity C3. Both cavities C1 and C2 go closer to zero occupancy 
after 17 ns due to ligand escaping to the solvent. But for cavity C3 the ligand tends to remain in 
the cavity during the complete simulation time. Therefore our simulations results agree with the 
above mid-infrared probe. 
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Figure 47 Dynamics of the Ligand.  Panels a, b and c show the drawn path of combined 
trajectories of the ligand around the heme plane, during the first 5 ns after the CO-Fe bond 
remotion. In panels d, e and f the number of contacts between the residues within the protein 
region defined in the y-axis and the ligand are shown. 
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Figure 48 Probability of the Ligand to Stay inside the Cavities after the Fe-CO Bond Breaking 
Event. The probabilities include all the 18 proteins in the crystal simulation (the initial time after 
bond breaking do not add up to 100% because for some proteins the ligand escape almost 
immediate after the bond is broken or the ligand is outside any of the three cavities). 
Probabilities increases (after a slight decrease) are due to ligand motion away cavity area and 
subsequent oncoming. 
 
Conclusions  
In this work we have performed MD simulations of CO unbounding from the heme 
pocket of bjFixLH in aqueous solution and in a crystal cell. Different results after CO 
dissociation were observed in the two environments.  
For half of the proteins in the crystal simulations the ligand remains inside the binding 
cavity during the complete CO-unbound simulation, whereas relaxation to the deoxy state occurs 
for those proteins where the carbon monoxide escapes to the solvent and for the aqueous solution 
simulation. For the protein where the ligand stays after Fe-CO bond breaking hydrophobic 
residues that surround the ligand keep it within the heme pocket in sort of a “cage”. 
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 Escape of CO is related to the break of the salt bridge between Arg220 and HP7, so 
Arg220 is acting as a “gate” of the protein cavity.  
Conformational changes observed in previous experiments by liganded and unliganded 
structures of this protein are observed in our simulations but with an important dependence on 
the location of the ligand after bond dissociation. In turn, the location of the ligand after 
dissociation depends on the intrinsic motions and fluctuations of the protein just before the bond 
breaking event.  
Three possible cavities in the heme plane have been found in our simulations, with cavity 
C3 being more effective in keeping the ligand close to the heme group after bond breaking. 
Further simulations with enhanced sampling techniques of wild type and mutant species will be 
needed to corroborate our findings and suggests new experimental observations to elucidate the 
signal transduction pathway of this oxygen sensing enzyme. 
Computational Methods 
Solution Simulations 
Initial coordinates were taken from the 2.4 Å resolution crystal structure of the CO-bound 
BjFixLH (PDB entry 1lsv)24, which is the isolated heme-PAS domain of the dimeric oxygen 
sensor BjFixL that consists of 130 amino acids. Molecules and structure files were prepared 
using VMD program22. Simulations were performed with NAMD 2.6 code25 and CHARMM27 
force field26. All the glutamic and aspartic acid residues and the heme prosthetic groups were 
taken to be deprotonated while all the lysines and arginines were protonated. The histidine side 
chains were modeled as neutral with the δ nitrogen protonated, in order to model a solution at pH 
7.5, the pH that was used to prepare the crystals24. Periodic boundary conditions were used 
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placing the initial structure in an equilibrated water box of dimensions 68x67x52 Å3. To create a 
neutral simulation box, 6 Na+ counterions were added by replacing water molecules at the most 
negative electrical potential. The total system size was 1835 protein atoms, 75 heterogen atoms 
(heme and ligand), 6 sodium counterions and 6836 TIP3P water molecules, leading to a total of 
22424 atoms. The minimization, heating and equilibration of the system were completed during 
1100 ps. The system was minimized using the conjugate gradients method, and then was heated 
by increments of 0.001K every time step (2fs) up to 287K for 600ps. Next, the system was 
equilibrated at constant volume for 400 ps. A standard MD trajectory 10 ns long, at constant 
pressure and temperature, was performed with a bound CO, and this was followed for another 10 
ns trajectory with unbound CO. The integration time step was 2fs, van der Waals interactions 
were calculated every step (2fs) while electrostatics interactions were calculated every other step 
(PME every 4fs), using the multiple time step method employed by NAMD (Verlet-I/r-
RESPA/Impulse MTS Method)27. The Particle Ewald Mesh summation for long range 
electrostatic interactions was used with the number of grid points of 64(26) in the x, y and z 
dimensions accordingly with the periodic box size. The cutoff distance for van der Waals was 
12Å. A non-bonded pair list cutoff of 13.5Å and the pairlist was updated every 10 time steps. 
The pressure was controlled using the Nosé-Hoover Langevin piston pressure control25. The first 
10 ns of each run were performed using force-field parameters for a six-coordinated heme while 
for the final 10 ns domed, five-coordinate heme force field parameters were used28, 29. Atomic 
coordinates were stored every 1ps for data analysis. Three different simulation replicates were 
computed.  
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Crystal Simulation 
The starting coordinates for this simulation was the crystal structure of the CO-bound 
BjFixL heme domain. This crystal belongs to the H32 space group, with the following 
rhombohedral cell parameters a=b=127.01Å, c=58.14Å, α=β= 90°, γ=120°20. The H32 crystal 
unit cell contains 18 symmetry related molecules; therefore the initial coordinates of the crystal 
unit cell were obtained by applying the H32 symmetry transformation30. The 18 proteins were 
hydrated by placing 684 water molecules at crystallographic sites and 16116 at 
noncrystallographic sites31, in order to have a box density close to the experimental value 
(59.31%v/v). A total of 107 Na+ counterions replaced water molecules at the most 
electronegative potential sites to get a neutral simulation box. The number of protein atoms was 
33030, heterogen atoms 1350, 48027 atoms from water molecules and 107 sodium atoms for a 
total number of 82514 atoms. Basically the same protocol described for the solution simulations 
was employed for the crystal unit cell run. The solvent was relaxed by energy minimization and 
brought to a temperature of 287K assigning increments of 0.001K every time step (2fs), during a 
700ps run while restraining the protein, heme and CO initial positions with a harmonic potential. 
The system was then minimized gradually lowering the restraining force constant to zero during 
four 100ps runs and heated to 287K without restraints. The same process as of minimization was 
employed for the system equilibration at constant volume in a stepwise manner equilibrating the 
solvent and then the complete system. A 20 ns MD run was done at constant P and T, with the 
same parameters used in the solution simulation. A feature observed during previous simulations 
(that we also observe in the simulations we are reporting here) was the deformation of the unit 
cell. Previous crystal molecular dynamics simulations, at constant volume and pressure, have 
shown that these simulations are sensitive to several model parameters that lead to smaller 
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distortions in shape and size18. In order to study the effect of these deformations in our crystal 
simulations, an additional simulation using harmonic constraints applied to the proteins 
backbone was done. 
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